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abbREViaTiONS
AdAM a disintegrin and metalloprotease
ALdH1 aldehyde dehygrogenase 1
ALK activin-like kinase
Asp aspartate
BAC	 Bacterial	Artificial	Chromosome
Becs blood endothelial cells
BL Burkitt’s lymphoma
BM bone marrow
BMP bone morphogenetic protein
bp base pair
CAFs		 cancer	associated	fibroblast	
cAMK calcium/calmodulin-regulated kinases
cdK cyclin-dependent kinase
cKI cyclin-dependent kinase inhibitor
cScs cancer stem cells
cSF1 colony-stimulating factor 1
cTL cytoxic T Lymphocytes
de delayed early
DMEM	 Dulbecco’s	modified	Eagle	Medium
eBV epstein-Barr virus
ecM extracellular matrix
ecs endothelial cells
eGF epidermal growth factor
eMSA electrophoretic mobility shift assay
eMT epithelial–mesenchymal transition
endMT endothelial-mesenchymal transition
epcAM epithelial cell adhesion molecule
FACS	 fluorescence-activated	cell	sorting
FAP	 fibroblast-activated	protein
FcS fetal calf serum
FGF	 fibroblast	growth	factors
FSP1/S100A4	 fibroblast-specific	protein-1
Fzd Frizzled
G-cSF Granulocyte colony-stimulating factor
GeM gene expression microarray
GFP	 green	fluorescent	protein
GM-cSF granulocyte–macrophage colony-stimulating factor
GPI glycosylphosphatidylinositol
GSK glycogen synthase kinase
GST Glutathione-S-transferase
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HAART Highly Active Anti-Retroviral Therapy 
HAT histone acetyltransferases
HBV hepatitis B virus
Hcc hepatocellular carcinoma
HcS high-content screening
HcV hepatitis c virus
HdAc histone deacetylase
HGF hepatocyte growth factor
Hh Hedgehog pathways
HHV-8 human herpesvirus type 8
HIF-1 hypoxia induced factor 1
HIV	 Human	immunodeficiency	virus
HPcs hematopoietic progenitor cells
HPV human papillomavirus
HSP90 heat shock protein 90
HTLV-1 human T-cell leukemia virus
HUVec human umbilical vein endothelial cells
Ie immediate early
IGF1 insulin-like growth factor 1
IGFR insulin growth factor receptor
IL-8 interleukin-8
KS Kaposi’s sarcoma
KSHV Kaposi’s sarcoma herpesvirus
LAnA latency-associated nuclear antigen
LBS LAnA binding sites
Leu leucine
LT latency transcript
Lec lymphatic endothelial cells
Lef/Tcf lymphoid enhancer factor/T cell factor
LYVe-1 lymphatic vessel hyaluronan receptor-1
Mcd multicentric castleman disease
McP monocyte chemoattractant protein
McPyV Merkel cell polyomavirus
MdM2 murine double minute 2
MEF	 mouse	embryo	fibroblast
miRnA microRnA
MMP matrix metalloproteinases
MoI multiplicity of infection
MoMuLV moloney murine leukemia virus
mRnA messenger RnA
MT-MMP membrane- bound MMP
MT1-MMP membrane-bound type 1 MMP
naB sodium butyrate
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nF-kB nuclear factor kappa-B
nG2 neuron-glial antigen-2
nIcd notch intracellular domain
nK natural-killer cells
nLS nuclear localization signal
nod non-obsese diabetic
nPM nucleophosmin
n-terminal aminoterminal
oRc origin recognition complex
oRF open reading frame
PAGe polyacrylamide gel electrophoresis
PAn polyadenylated nuclear 
PcnA proliferating cell nuclear antigen
PcR polymerase chain reaction
PdGF platelet derived growth factor
PdGFR platelet derived growth factor receptor
PdGFR-a platelet derived growth factor receptor alpha
PdGFR-b platelet derived growth factor receptor beta
PecAM1 platelet/endothelial cell adhesion molecule 1
PeL primary effusion lymphoma
PFA paraformaldehyde
PI3K phosphatidylinositol 3 (PI3)-kinase
PKA protein kinase A
PKc protein kinase c
proline Pro
Rb retinoblastoma
RBPJ recombination signal binding protein for immunoglobulin kappa J region
RFP	 red	fluorescent	protein
RnA ribonucleic acid
RnAi RnA interference
RTA replication transcriptional activator
s.c. subcutaneous
SA signal anchor
SCID	 severe	combined	immunodeficiency
SdF1 stromal-cell-derived factor 1
Ser serine
sh-RnA short hairpin RnA
SUMO	 small	ubiquitin-related	modifier
SV40 Simian virus 40
TA transactivation
TAM tumor associated monocyte/macrophage
TGF-b transforming growth factor beta
Thr threonine
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TIMPs the tissue inhibitors of metalloproteinases
TNF-α	 tumor	necrosis	factor	alpha
TP53 tumor protein 53
TPA 12-o-tetradecanoyl phorbol-13-acetate
TR terminal repeat
Trp tryptophan
TSA trichostatin A
TSP-1 thrombospondin-1
UV ultraviolet
v-cyclin viral cyclin
VeGF vascular endothelial growth factor
VeGFR vascular endothelial growth factor receptor
v-FLIP viral FLIce-inhibitory protein
vGPcR viral G protein-coupled receptor
vIL-6 Viral interleukin-6
vIRF Viral interferon regulatory factor
VSVG vesicular stomatitis virus G protein
wt wild type
XIAP X-linked inhibitor of apoptosis
Zo-1 zonula occludens 1
aSMA a-smooth-muscle actin
b-gal b-galactosidase
2d 2-dimentional
3d 3-dimentional
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abSTRaCT
Kaposi’s sarcoma herpesvirus (KSHV) is the etiological agent of three types of 
malignancies: Kaposi’s sarcoma (KS), multicentric castleman disease (Mcd), and 
primary effusion lymphoma (PeL). Infection by KSHV displays two different phases: 
latent and lytic replication phase. By using an unbiased gain-of-function human kinome 
cDNA	screen,	the	work	in	this	thesis	identified	two	kinases,	Pim-1	and	-3,	to	be	involved	
in KSHV reactivation. ectopic expression of Pim-1 and Pim-3 induced viral lytic 
replication leading to production of progeny viruses, whereas depletion of Pim-1 and 
Pim-3 by RnA interference inhibited the induction of lytic reactivation. Pim-1 and -3 
was shown to regulate viral reactivation by phosphorylation of LAnA, which abolished 
the LAnA-mediated repression of lytic transcription. 
In this thesis project we developed a novel three-dimensional (3d) cell model to 
identify novel oncogenic processes involved in the KSHV-induced endothelial cells 
(ec) transformation. The results demonstrate that KSHV induces transcriptional 
reprogramming of primary lymphatic endothelial cells (Lecs) to mesenchymal cells 
via endothelial-to-mesenchymal transition (endMT), a process implicated in promoting 
tumor growth and cell invasiveness. Two viral gene products, vFLIP and vGPcR, were 
found to trigger notch signaling and lead to the KSHV-induced endMT. our data further 
identifies	a	membrane	associated	matrix	metalloproteinase	MT1-MMP	as	a	previously	
unrecognized regulator downstream of notch to induce endMT. 3d KSHV-infected Lecs 
(K-LECs)	transcriptome	showed	significant	up-regulation	of	invasion	related	genes	that	
were found co-regulated in 3d K-Lecs and KS biopsies. The results further demonstrate 
that 3d culture provides a permissive microenvironment for continuous viral replication 
and persistence. To summarize, this Phd thesis greatly expands the understanding of 
host signaling pathways involved in KSHV reactivation and oncogenesis. Furthermore, 
this thesis provides novel information about cellular targets for pharmacological control 
in KS and other virus-associated cancers.
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iNTROduCTiON
KS is the most common cancer in HIV-infected untreated individuals and remains a 
primary cause of cancer deaths in many subequatorial African countries as a result of 
the AIdS pandemic. KS displays an extraordinary diversity of cell types ranging from 
endothelial to mesenchymal cells of unclear origin. during the last decade KS tumor 
cells have been thought to be of endothelial origin, and immortalized ecs infected with 
KSHV	 lose	 cell	 contact	 inhibition,	 can	 grow	 post-confluently,	 form	 foci	 in	 soft-agar	
and even form tumors in nude mice, which are hallmarks of cellular transformation. 
However, infection of primary Lecs by KSHV does not cause a similar transformed 
phenotype when maintained in standard monolayer cell culture, but rather tend to lose 
viral episomes, suggesting that the tumorigenic potential of KSHV on the endothelium 
may be dependent on the culture microenvironment. As with other herpes viruses, 
infection by KSHV displays these two phases. during latency only few viral genes are 
expressed, while in the productive infection the virus is reactivated with initiation of 
extensive viral dnA replication and gene expression, resulting in production of new 
viral particles, contributing to progression of KS. Host signal-transduction pathways are 
intimately involved in the switch between latency and productive infection of herpes 
viruses, but they have not been rigorously addressed.
The emphasis of this Phd thesis is to illustrate the importance of virus-cell interactions 
in	KSHV	spread	and	viral	 induced	oncogenesis.	 In	 the	first	part	of	 the	 thesis,	 I	have	
investigated cellular kinases regulating the switch from latency to lytic replication of 
KSHV by systematically screened the effect of expression of 466 human kinases on 
KSHV reactivation. In addition, I have examined cellular processes involved in KSHV 
pathogenesis by using a 3d model for KSHV-infected primary Lecs to mimic important 
aspects of the tissue environment. The experimental part of my Phd thesis gives novel 
insight into molecular mechanisms involved in KSHV pathology, which can be used for 
developing targeted therapies to prevent or at least slow down the progression of KS in 
immunosuppressed patients. 
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REViEW OF THE liTERaTuRE
1. Kinase signaling pathways
1.1. Human kinome
Since the discovery of protein phosphorylation nearly 50 years ago, protein kinases have 
been recognized as major players in cell signaling, accounting for ~2% of genes in the 
human genome (Manning et al., 2002b). By phosphorylating substrate proteins, kinases 
modify	the	activity,	location	and	affinities	of	up	to	30%	of	all	cellular	proteins,	and	direct	
most of the cellular processes, particularly in signal transduction and co-ordination of 
complex pathways. Mutations and dysregulation of protein kinases play causal roles 
in human disease, offering the possibility to develop agonists and antagonists of these 
enzymes for use in disease therapy (Hunter and cooper, 1985).
All the mammalian protein kinases can be divided into tyrosine kinases, serine/threonine 
kinases, and kinases that can phosphorylate both tyrosine and serine/threonine residues. 
Despite	these	differences	in	substrate	specificity,	all	known	mammalian	protein	kinases	
have structurally similar kinase domains (Huse and Kuriyan, 2002; nolen et al., 2004). 
The kinase domain is composed of 250-300 amino acid residues and can be divided 
into two subdomains, a smaller n lobe and a larger c lobe, between which is the cleft 
into which ATP and the substrates bind (Huse and Kuriyan, 2002; nolen et al., 2004). 
The relatively strong conservation of kinase domains has allowed the computational 
characterization of the protein kinase complement of the human genome, and for most 
kinases,	 also	 the	 identification	of	 critical	 residues	 required	 for	 their	 catalytic	 activity	
(Manning et al., 2002b). These residues include a lysine (Lys72 in PKA) in the n lobe, 
which is required for proper orientation of ATP, and an aspartate (Asp166 in PKA) in 
the catalytic loop, which interacts with the hydroxyl side chain of the substrate (Huse 
and Kuriyan, 2002). Mutations in these residues kill the catalytic activity of kinases 
(Manning et al., 2002a), but do not interfere with substrate recognition or binding to 
other proteins. As a result, catalytically inactive kinase can either have no activity, or 
dominant-negative activity due to titration of cofactors from the corresponding active 
kinase (Mendenhall et al., 1988).
certain mutations in a subset of kinases (such as eGFR, c-Met, c-Kit, and 
Phosphatidylinositol 3 (PI3)-kinases (PI3K)) change the expression, conformation and/
or stability of these kinases, leading to constitutive activation of these kinases and related 
signaling pathways. For instance, a key PI3-kinase gene PIK3cA is found to be mutated 
frequently in human cancer. Most of these mutations are heterozygous missense changes 
clustered in the helical region and in the catalytic domains of the gene, which affect 
highly conserved residues within these domains. These mutations were shown to cause 
constitutive activation of PI3K as well as enhanced phosphorylation of downstream 
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target AKT in tumor cells, which contribute to the malignant transformation, growth, 
and metastasis of human cancers (Lengyel et al., 2007; Samuels et al., 2005).
So far there are more than 620 protein kinase complement in the Human Genome 
(the	human	‘‘kinome’’)	identified	by	different	genomic	approaches.	These	kinases	are	
classified	 into	 nine	major	 classes	with	 90	 families	 and	 145	 subfamilies	 by	 sequence	
comparison of their catalytic domains, aided by knowledge of sequence similarity and 
domain structure outside of the catalytic domains, known biological functions, and a 
similar	 classification	 in	 the	 yeast,	worm,	 and	 fly	 kinomes	 (Hanks	 and	Hunter,	 1995;	
Manning et al., 2002a) (http://www.kinase.com/human/kinome/). deciphering the 
complex network of phosphorylation-based signaling is essential in understanding 
fundamental cellular processes in physiological and pathological states, providing a 
thorough knowledge base for therapeutic intervention.
1.2. Human kinases as the therapeutic targets of cancers
Human kinases are intimately involved in cancer cell growth, proliferation, survival 
and evasion. deregulation of kinase activity has emerged as a major mechanism in the 
development of different types of cancers (Hanahan and Weinberg, 2011). Among the 
most frequently mutated oncogenes and tumor suppressors, human protein kinases have 
become the largest class of new drug targets. In recent 10 years, there are more than 
10,000	 patent	 applications	 for	 oncogenic	 kinase	 inhibitors	 being	 filed	 in	 the	 United	
States alone, a dozen of kinase inhibitors being proved as cancer treatments, and more 
kinase targets being developed at the clinical or preclinical stage (Akritopoulou-Zanze 
and Hajduk, 2009; Zhang et al., 2009). 
one such exciting advance in cancer therapy is the discovery of Bcr-Abl gene fusion 
and the subsequent development of imatinib mesylate, a small molecule tyrosine kinase 
inhibitor, to target the catalytic activity of the bcr-abl protein product in chronic myeloid 
leukaemia (cML) (Roychowdhury and Talpaz, 2011). This inhibitor was later used to 
effectively target mutant c-Kit in gastrointestinal stromal tumors (GIST) and a few other 
tumors, leading to multi-year increases in survival of patients. It is encouraging that this 
protein-kinase inhibitor is achieving unprecedented durability for complete hematologic, 
cytogenetic, and molecular responses and proving to be well tolerated compared to 
conventional chemotherapeutic treatments.  
However,	 about	 half	 of	 the	 patients	 who	 initially	 benefit	 from	 imatinib	 treatment	
eventually develop drug resistance because of the acquisition of secondary mutations 
in the kinase domain, the activation of surrogate kinases that substitute for the drug 
target or the presence of activating mutations in downstream pathway components. 
overcoming these resistance mechanisms may require targeting tumor cells at multiple 
levels by using either single drugs that inhibit multiple proteins or cocktails of several 
selective kinase inhibitors. Indeed, a new c-Kit inhibitor sunitinib, which also targets 
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VeGF receptor (VeGFR) and platelet derived growth factor receptor alpha (PdGFR-a), 
has	proven	efficacious	in	patients	who	are	intolerant	or	refractory	to	imatinib.
The future efforts in salvaging patients from failure of the kinase inhibitor monotherapies 
is to learn how to identify larger panels of kinases and related signaling components 
that are implicated in cancer, how to predict the best combinations of these targets and 
then how to prioritize those combination and develop agents with multiple targets to 
overcome tumors resistant against a single-targeting agent.
1.3.	 Functional	genomics	for	identification	of	kinome	targets	in	virus-
associated cancers
Advances	in	genomic	technologies	have	opened	up	the	field	of	systematic	identification	
of novel human genes required for tumor formation and progression in mammalian cells. 
RnA interference (RnAi) is a RnA dependent gene silencing process in which short 
double-stranded RnA molecules lead to either degradation or translational arrest of 
target mRnAs in a cell. The selective and robust effect of RnAi on gene expression can 
be	exploited	as	a	research	tool	by	transfecting	siRNAs	designed	to	target	specific	genes	
into a cell and evaluating the effect of knocking down the expression of these genes on 
a cellular process (dorsett and Tuschl, 2004). The development of large-scale RnAi 
screens has made it possible to get an unbiased tumor signaling network by looking 
for genes that are crucial for tumor growth. In addition, these screens facilitate the 
identification	of	new	kinase	targets,	as	any	gene	that	selectively	blocks	tumor	growth	
when knocked down by RnAi is a candidate. As a complementary tool, the special 
collection of kinome cdnA library could be used to systematically screen for kinases 
affecting a given cellular phenotype. Because increased kinase expression often leads 
to gain-of-function phenotypes due to increased activity, the special collection of the 
kinome cdnA library could also be used to systematically screen for kinases affecting 
a given cellular phenotype, or to validate the kinase hits obtained from RnAi screens.
To date, accumulating evidences suggest that at least seven different human viruses-- 
epstein-Barr Virus (eBV), hepatitis B virus (HBV), human papillomavirus (HPV), human 
T-cell leukemia virus (HTLV-1), hepatitis c virus (HcV), Kaposi’s sarcoma herpesvirus 
(KSHV)	and	Merkel	cell	polyomavirus	(MCPyV)	are	bona	fide	etiologic	agents	of	human	
malignancy, contributing to 15-20% of human cancers worldwide (McLaughlin-drubin 
and Munger, 2008). Human tumor viruses have served as important experimental models 
in understanding key molecular events in multi-step tumor development and progression. 
RnA and dnA viruses differ in their general mechanisms of inducing tumorigenesis, 
partially due to the difference in their replication mode and life cycle. The studies of viral 
proto-oncogenes have led to the discovery of their cellular counterparts, oncogenes and 
relevant cellular growth-regulatory networks, whereas research on dnA tumor viruses 
has	inspired	further	identification	of	p53	tumor	suppressor	and	many	functions	of	the	
retinoblastoma (Rb) tumor suppressor. 
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Given that the genome size of a virus is highly restricted to ensure packaging within 
an infectious structure, viruses need to target host cellular signaling pathways that 
control proliferation, differentiation, cell death, genomic integrity, tumor invasion and 
immune surveillance in cancer progression (McLaughlin-drubin and Munger, 2008). 
our understanding of how these viruses exploit cellular genes and pathways has not 
only contributed to our knowledge of viral pathogenesis, but also revealed much of the 
molecular mechanisms within the cell.
In spite of the effectiveness of antiviral regimens targeting viral infection, broad-
spectrum antiviral drugs have been elusive due to the rapid evolution of viruses and low 
fidelity	of	viral	proteins.	A	promising	pharmacological	strategy	for	treating	individuals	
living with tumor viruses has been to simultaneously target host factors required for virus 
infection or replication. However, the identity of these virus associated host factors and 
signaling pathways remains incompletely understood (Goff, 2008; Lama and Planelles, 
2007). Therefore, unbiased, genome-scale research into cellular factors associated with 
viral replication and pathogenesis will provide new insight into the multiple functions of 
cellular pathways, offering the potential to further understand virus-host interactions and 
identify host targets for developing anti-virus therapeutics. 
With the advent of cell-based screening technologies, it has become possible to screen for 
cellular	protein	kinases	required	for	viral	infection	in	a	given	host	cell	during	a	bona	fide	
viral	life	cycle,	rather	than	in	simplified	in vitro systems. In the last few years, a series of 
genome-scale screens have been performed against human oncogenic viral pathogens. 
This	has	led	to	the	identification	of	a	large	number	of	new	host	cell	proteins	and	pathways	
that	influence	different	phases	of	viral	life	cycles.	This	work	has	greatly	expanded	our	
knowledge of the interface between each virus and its host, and will undoubtedly lead 
to insight into the cell biological roles of many of these genes. of particular interest is 
the fact that several screens have been carried out in cells infected with the same type of 
viruses such as HIV and HcV, allowing analysis of the reproducibility and robustness of 
the screening technique.
1.3.1. HiV screens
Patients with HIV infection have a severely compromised immune system and show 
substantially increased incidence of several cancers, primarily due to co-infection with 
an oncogenic dnA virus, especially eBV, KSHV and HPV (Boshoff and Weiss, 2002; 
Yarchoan et al., 2005). To date, four independent screens have been published identi-
fying host factors important in different phases of the HIV lifecycle (Brass et al., 2008; 
König et al., 2008; Yeung et al., 2009; Zhou et al., 2008), as well as a meta-analysis 
further examining the combined results of three of these studies (Bushman et al., 2009).
Two of these screens were performed in HeLa cells with quite a similar strategy, although 
the studies used different siRnA libraries (Brass et al., 2008; Zhou et al., 2008). In the 
first	screen,	by	Brass	et	al.	the	assay	was	based	on	p24	Gag	expression	making	it	sensitive	
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to all of the early phases of HIV replication. The late-acting host factors affecting viral 
assembly and egress were assayed by culturing of infected cell supernatants with fresh 
Tat-responsive cells and using tat mediated b-galactosidase activity as a second measure 
of	productive	infection.	From	the	first	screen,	the	authors	identified	genes	inhibiting	p24	
Gag production that fell into classes spanning many aspects of cell biology, from nuclear 
pore components, autophagy, the mediator complex (an RnA-polymerase II-associated 
complex	 involved	 in	 activation	of	 transcription)	 to	 vesicular	 trafficking	 (Brass	 et	 al.,	
2008). In the second screen, by Zhou et al. the authors assessed the virus infection and 
tat activation by following a tat-responsive b-gal reporter expression (Zhou et al., 2008). 
Interestingly,	only	15	of	the	identified	genes	were	among	those	also	identified	by	Brass	
et al.	in	the	first	screen.	Seven	of	the	15	overlapping	genes	were	previously	identified	
as playing a role in HIV replication, including the viral receptors cd4 and cXcR4. In 
addition,	several	com	ponents	of	the	mediator	complex	identified	by	Brass	et al., as well 
as	other	components	of	this	complex,	were	identified	in	this	screen,	further	confirming	
the	 role	 of	 the	mediator	 complex	 in	HIV	 replication.	Another	 set	 of	 identified	genes	
validated by cdnA rescue were involved in Akt/nFkB signaling, although the step in 
the life cycle was not addressed.
A complementary approach to RnAi loss-of-function screening is to perform arrayed 
cdnA screening to identify gain-of-function activities. A screen by nguyen et al. 
used the same HeLa cell line as Brass and Zhou, and cotransfected a library of 15 000 
human cdnAs along with a tat-responsive luciferase reporter (nguyen et al., 2007). 
The	authors	identified	315	genes	increasing	the	tat-mediated	luciferase	production	upon	
overexpression, and these were genes involved in mitochondrial biology, transcription, 
translation, and antiapoptotic functions. Three out of the six top candidates were found 
to be required for replication when siRnAs were tested, validating this approach.
1.3.2. HCV screens
The Flaviviridae family member Hepatitis c virus (HcV) chronically infects 
approximately 170 mil lion people worldwide. HcV infection is the leading cause of 
chronic liver disease and associated with an increased risk of primary liver cancer. Given 
the importance of better anti-HcV therapies, many groups have launched genome wide 
screen approaches to identify cellular cofactors of the virus life cycle, with a hope to 
develop novel therapeutics (Berger et al., 2009; ng et al., 2007; Randall et al., 2007; 
Supekova et al., 2008; Tai et al., 2009; Trotard et al., 2009). 
ng et al. screened a library of 4000 druggable genes using Huh-7 derived cells that 
stably maintain a HcV subgenomic replicon expressing HcV nS3- nS5B and the 
reporter secreted alkaline phosphatase (SeAP) (ng et al., 2007). nine cellular genes that 
potentially	regulate	HCV	replication	were	identified	through	the	screen	and	a	re-screen,	
four of which are members of the TnF/LT signaling pathway, making this pathway 
a potential target for anti-HcV therapeutics. In addition, there were two small-scale 
 Review of the Literature 19
screens to identify cellular factors regulating HcV replicon replication, due to technical 
difficulties	in	working	with	the	infectious	virus	(Berger	et	al.,	2009;	Randall	et	al.,	2007).
To date, however, only one study has used a siRnA library cover ing the entire genome 
(Tai et al., 2009). This screen was carried out in Huh-7 cells harboring an HcV 
luciferase-expressing replicon, examining viral pro tein expression and RnA replication. 
96	human	genes	that	support	HCV	replication,	with	a	significant	number	of	them	being	
involved	 in	 vesicle	 organization	 and	 biogenesis	were	 identified	 through	 primary	 and	
secondary	 screens,	 including	 several	 previously	 identified	 puta	tive	HCV	host	 factors	
such as phosphatidylinositol 4-kinase PI4KA and multiple subunits of the coPI vesicle 
coat complex (Gosert et al., 2003). Interestingly, Supekova et al. (Supekova et al., 2008) 
screened the human kinome (510 genes) for their role in HcV replicon replication using 
a similar assay to Tai et al. in the genome-wide screen (Tai et al., 2009). Validation of 
the	hits	derived	from	this	screen	identified	three	novel	kinases	CSK,	JAK1,	and	VRK1	
required	for	HCV	replicon	propagation,	which	were	not	 identified	as	hits	 in	previous	
screens described above.
1.4. pim kinase family
1.4.1. discovery of pim kinase family
The human Pim serine/threonine kinase family belongs to the group of calcium/
calmodulin-regulated kinases (cAMK), which are highly conserved through evolution 
in multicellular organisms. Three Pim family members Pim-1, Pim-2 and Pim-3 share 
significant	sequence	similarities	and	homologous	structures	(containing	a	characteristic	
kinase domain, an ATP anchor and an active site) and largely overlapping functions 
(Bachmann and Moroy, 2005; Bullock et al., 2005). 
The pim-1 gene	was	originally	identified	as	a	preferential	proviral	insertion	site	of	the	
Moloney	Murine	Leukemia	Virus	in	experiments	designed	to	find	new	genes	involved	
in murine T-cell lymphomas (Selten et al., 1985). In subsequent experiments, Pim-
1,	Myc	and	Gfi1	in	each	combination	were	shown	to	have	 the	ability	 to	cooperate	 in	
experimental T-cell lymphomagenesis (Allen and Berns, 1996), establishing Pim-1 
as a proto-oncogene and important player in the process of malignant transformation. 
Further,	Pim-2	was	also	identified	as	a	proviral	integration	site	associated	with	a	rapid	
development of malignant T-cell lymphomas.
1.4.2. Function and regulation of pim kinases
Pim kinases are able to phosphorylate different targets, most of which are involved in 
multiple cellular functions such as cell growth, differentiation and apoptosis. Several 
Pim-1	substrates	have	been	 identified	over	 the	 recent	years	 including	nuclear	adapter	
protein p100 (Leverson et al., 1998), T-cell receptor transcription factor nFATc (Rainio 
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et	al.,	2002),	the	pro-apoptotic	protein	Bad	(Aho	et	al.,	2004)	and	G1-specific	cell	cycle	
regulator cdc25A (Losman et al., 2003).
expression of Pim kinases can be stimulated by a large set of cytokines and regulated at 
transcriptional, post-transcriptional, translational and post-translational levels. Several 
signal transduction pathways such as the JAK/STAT axis may be important for Pim-
1 expression. For instance, STAT3 activated via different cytokines or growth factors 
such as IFn-l, c-Kit, ScF, GcSF and eGF, binds directly to the pim-1 promoter at the 
ISFR/GAS-sequence (gamma interferon activation sequences), which leads to an up-
regulation of pim-1 gene expression. In addition, Pim-1 itself can negatively regulate 
the Jak/STAT pathway by binding to a group of negative regulators of STAT activity, the 
so-called SocS proteins (Losman et al., 1999), which implicates the role of Pim-1 in 
immune responses.
1.4.3 pim kinases and tumorigenesis
The Pim kinases are involved in a number of signaling pathways that control critical 
processes in hematogenesis and lymphopoiesis, which have implications in tumor 
development. Indeed, Pim kinases are overexpressed in various lymphomas and 
leukemias (Amson et al., 1989; Hoefnagel et al., 2005) as well as in prostate cancer 
(dhanasekaran et al., 2001). examples for a possible involvement of Pim-1 in human 
tumors are prostate cancer, oral cancer and Burkitt lymphoma (Gaidano et al., 1993).
Recent results have implicated Pim kinases in regulation of herpesviral oncogenesis. 
expression levels of Pim-1 and Pim-2 are upregulated upon eBV infection and they in 
turn enhance the activity of the viral nuclear antigen eBnA2, suggesting roles in eBV-
induced immortalization and tumorigenesis (Rainio et al., 2005). In addition, KSHV 
infection has been shown to enhance expression of Pim-2 in cd34+ bone marrow cells 
(Mikovits et al., 2001).
Pim-1-deficient	mice	generated	by	gene	targeting	did	not	show	a	pronounced	phenotype	
except subtle changes in cytokine signaling. A triple knock out mouse of all three Pim 
genes was found to be viable and fertile but still lacks a strong phenotype save for 
a reduction of body size and moderate defects in growth factor signaling and T-cell 
proliferation (Mikkers et al., 2004). These in vivo results suggest the suitability of Pim 
kinases as drug targets in therapeutic measures.
2. Tumor microenvironment
In past decades, research on the biology of cancer has mainly focused on the tumor cells 
themselves. Accumulation of mutations gives the cells the ability to grow out of control, 
move out and metastasize at distant sites. However, the switch from a normal to malignant 
state is driven not just by what is happening within the tumor cell itself but also by what 
is happening around it. More recently tumors have gradually been regarded as complex 
 Review of the Literature 21
organs in which multiple specialized cells, components and molecules that surround the 
tumor	area	construct	the	‘‘tumor	microenvironment’’	influencing	the	course	of	multistep	
tumorigenesis. A set of cell types and components in the tumor microenvironment are 
described in Figure 1 as important contributors in the process of tumor progression 
(Lorusso and Ruegg, 2008).


















	

		

	  
		



Figure 1. Heterotypic cellular interactions in Tumor microenvironment. Tumor cells 
orchestrate	 the	 modification	 of	 the	 microenvironment	 by	 attracting	 or	 activating	 many	 non-
tumoral cells and in turn, tumor microenvironment promotes tumor progression by stimulating 
tumor growth, survival and angiogenesis, and facilitating invasion and metastasis via eMT and 
maintenance of cScs. The interaction between tumor cells and microenvironment determine the 
outcome of tumor progression: tumor growth, tumor dormancy, tumor invasion and metastasis 
and resistance to therapy. Abbreviations: B, B lymphocyte; BMdc, bone marrow-derived cells; 
BV,	blood	vessel;	CAF,	 cancer	 associated	fibroblast;	EC,	 endothelial	 cell;	ECM,	extracellular	
matrix; eMT, epithelial to mesenchymal transition; Gr, granulocyte; Lec, lymphatic endothelial 
cell; LV, lymphatic vessel; MMP, matrix metalloproteinases; Mo, monocyte; cSc, cancer stem 
cell; Pc, pericyte; T, T lymphocyte; TAM, tumor associated monocyte/macrophage; Tc tumor 
cells	(Adapted	and	modified	from	Lorusso	and	Rüegg,	2008).
2.1. EMT/EndMT in the modulation of tumor microenvironment
2.1.1. The concept of EMT/EndMT
during embryonic development, epithelial cells must escape the structural constraints 
imposed by tissue architecture and adopt a phenotype more amenable to cell movement, 
a phenomenon known as the epithelial to mesenchymal transition (eMT). As a process 
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of cellular plasticity by which differentiated epithelial cells undergo a phenotypic 
conversion	that	gives	rise	to	the	matrix-producing	fibroblasts/mesenchymal	cells,	EMT	
is	 increasingly	recognized	as	an	 integral	player	of	 tissue	fibrogenesis	after	 injury	and	
initiating invasive and metastatic behavior in cancer cells. 
Under normal organ development or pathological conditions such as cancer and cardiac 
fibrosis,	 endothelial	 cells	may	 undergo	 a	 special	 form	of	EMT	 called	 endothelial-to-
mesenchymal transition (endMT) (Zeisberg et al., 2007). The cells undergoing endMT 
exhibit a wide range of phenotypic variability and plasticity depending on their location 
and function (chi et al., 2003). Besides being a crucial contributor during vascular 
development and remodeling (Arciniegas et al., 2007; Kizu et al., 2009), endMT in 
the	 tumor	microenvironment	was	 recently	 identified	as	 a	 candidate	 source	of	 cancer-
associated	 fibroblasts	 (CAFs)	which	may	 be	 essential	 to	 facilitate	 tumor	 progression	
(Potenta et al., 2008; Zeisberg et al., 2008).
2.1.2. phenotypic markers of EMT/EndMT
compelling cell-biological and molecular changes have been observed during the eMT/
EndMT	 program,	 being	 loosely	 defined	 into	 three	 cellular	 phenotypes	 (Boyer	 et	 al.,	
2000; Hay, 1995): (1) morphological changes from a cobblestone-like monolayer of 
epithelial/endothelial cells with an apical-basal polarity to depolarized, spindle-shaped 
mesenchymal cells with migratory protrusions; (2)biomarker changes, such as loss 
of cell–cell junction markers and certain epithelial/endothelial markers, and gain of 
mesenchymal markers and (3) the functional changes associated with the conversion of 
stationary cells to motile ones that can invade through the extracellular matrix.
In recent years, changes in the expression levels of a variety of biomarkers have been 
increasingly used to monitor eMT. The cadherin switch is one of the most important 
eMT biomarkers, where e-cadherin is switched into other types of cadherin such as 
n-cadherin during embryonic development and cancer progression, or oB-cadherin 
(OB	 for	 osteoblast)	 during	 fibrogenesis	 (Strutz	 et	 al.,	 2002;	 Zeisberg	 and	 Neilson,	
2009). b-catenin is a cytoplasmic protein linking cadherins to the cytoskeleton, which 
is	translocated	from	cell	membranes	to	cytoplasm	upon	EMT,	reflecting	its	dissociation	
from e-cadherin due to the cadherin switch (Brabletz et al., 1998). The tight junction 
protein zonula occludens 1 (Zo-1) is found to be downregulated on the cell membrane 
and relocalized to the cytoplasmic compartment upon eMT (Zeisberg and neilson, 
2009). Another eMT-linked process on cell surface is so called integrin switch, where 
various integrins are expressed on epithelial/endothelial and mesenchymal cells in a 
context-dependent manner (Bates and Mercurio, 2005; White and Muller, 2007).  
Several	 cytoskeletal	 markers	 also	 reflect	 changes	 upon	 EMT,	 including	 FSP1	 (a	
prototypical	fibroblast	marker	belonging	to	Ca2+-binding S100 protein family) (Iwano 
et	al.,	2002;	Zeisberg	and	Neilson,	2009),	vimentin	(intermediate	filament	expressed	in	
various	cells,	including	fibroblasts,	endothelial	cells,	cells	of	the	hematopoietic	lineages,	
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and glial cells) (Boyer et al., 1989; colucci-Guyon et al., 1994; Raymond and Leong, 
1989), and a-SMA (alpha smooth muscle actin, one of six actin family members expressed 
prominently	 in	vascular	smooth	muscle	cells,	myofibroblasts	and	myoepithelial	cells)	
(damonte et al., 2007; nakajima et al., 1997; Sarrio et al., 2008).
A	 few	 extracellular	 proteins	 serve	 as	 EMT	markers,	 of	which	 fibronectin	 appears	 to	
be a universal extracellular scaffold glycoprotein upregulated in various types of eMT 
(duband and Thiery, 1982; Hynes et al., 1982; Zeisberg et al., 2001). of the principal 
basement membrane constituents, laminin-1 is downregulated during eMT (Miner 
and Yurchenco, 2004; Zagris et al., 2005), whereas an increasing level of laminin-5 is 
associated with invasive cancers cells undergoing eMT (carpenter et al., 2008; Giannelli 
et al., 2005; Marinkovich, 2007). eMT biomarkers also contain signaling molecules 
involved in biological processes. The number of environmental eMT stimulating factors 
containing growth factors, ecM constituents, proteases, and hypoxia is increasing. In 
addition, eMT-associated downstream factors include a panel of transcription factors, 
such as Twist, HMGA2, LeF1, ets-1, FTS-1, cBF-A, KAP-1, Snail family members 
of	zinc	finger	proteins	(Snail1,	Snail2,	and	Snail3),	and	forkhead	box	family	(such	as	
FoXc2), which behave as potential key regulators of various signaling pathways to 
control the eMT response (Zeisberg et al., 2007).
2.1.3. EMT/EndMT signaling pathways in cancer progression
In cancer cells, multiple signaling pathways, including those triggered by different 
members of the transforming growth factor-b	(TGF-β)	superfamily,	Wnt,	Notch,	EGF,	
HGF, FGF, HIF, and many others induce common eMT-inducing transcription factors 
and in particular e-cadherin repressors associated with cell migration and invasion (Jing 
et al., 2011; Thiery and Sleeman, 2006; Yang and Weinberg, 2008) (see Figure 2).
The	TGF-β	signaling	pathway	has	been	implicated	as	a	major	EMT	signaling	pathway	
induced	 during	 cancer	 progression	 (Medjkane	 et	 al.,	 2009).	Members	 of	 the	TGF-β	
superfamily can activate and phosphorylate Smad2 and Smad3, which then form 
heteromeric complexes with Smad4 and translocate into the nucleus to control multiple 
EMT-inducing	 transcription	 factors	 through	 interaction	with	 specific	 binding	motifs	
in their gene regulatory regions, such as Snail, Slug, Zeb, SIP1 (derynck and Zhang, 
2003).	TGF-β	also	directly	 activates	various	 types	of	non-Smad	 signaling	 in	 certain	
types of tumor microenvironment, including Ras/eRK, JnK, PI3K, Par6, cdc42 
GTPases,	playing	important	roles	in	TGF-β-induced	EMT	(Miyazono,	2009;	Ozdamar	
et	al.,	2005).	 In	addition,	 the	TGF-β	pathway	 is	known	to	 interact	with	Notch,	Wnt,	
Hh and receptor tyrosine kinase signals to generate a complex, context dependent, 
and	reflective	network	required	for	EMT	in	various	tumor	progression	steps	(Guo	and	
Wang, 2009). 
24 Review of the Literature 









	













 
­







   


 

	 




 


Figure 2. Signaling pathways that orchestrate EMT in tumor microenvironment. In various 
tumor models in vitro and in vivo, eMT-inducing signals arising from the tumor-associated stroma 
lead	to	an	EMT-related	signaling	network	including	TGF-β,	Notch,	Wnt,	NF-κB,	tyrosine	kinases	
and others. These signalling pathways appear to be responsible for the induction or functional 
activation of a series of eMT-inducing transcription factors such as Snail, Slug, Zeb, Twist, 
Goosecoid, KLF8 and FoXc2. These transcription factors therefore change the global gene 
expression pattern of cells with a distinct phenotype and tissue function to facilitate movement of 
cells, invade local tissue, and enable genetically unstable cancer cells to acquire a mesenchymal 
phenotype	to	facilitate	local	and	systemic	dissemination		(Adapted	and	modified	from	Jing	et	al.,	
2011).
Both	 Wnt/β-caternin	 and	 Notch	 pathway	 have	 been	 implicated	 in	 modulating	 the	
eMT program during embryogenesis (Timmerman et al., 2004; Zavadil et al., 2004), 
and are also emerging as important regulators of eMT in carcinoma cells, as well as 
the maintenance of stemness properties of cancer stem cells (Malanchi et al., 2008). 
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In	canonical/β-catenin	Wnt	signaling,	Wnt	bind	to	Frizzled	(Fzd),	leading	to	β-catenin	
accumulation within the cell nucleus, where it interacts with the lymphoid enhancer 
factor/T cell factor (Lef/Tcf) complex leading to targeted gene transcription, including 
several eMT-inducing transcription factors such as Slug, Twist1, and Goosecoid. 
Inhibition of Wnt signaling can block eMT transcription factors and promote epithelial 
differentiation.
The notch pathway is a highly conserved cell signaling system present in most 
multicellular organisms. In humans, a diverse group of ligands from the delta (-1, 
-3 and -4) and Serrate/Jagged families (-1 and -2) recognize the extracellular domain 
of four notch receptors (notch 1, 2, 3, 4), inducing proteolytic cleavage through a 
disintegrin	and	metalloprotease	(ADAM)	followed	by	γ-secretase	cleavage	of	receptors,	
and releasing intracellular domain (nIcd). once released from the membrane receptor, 
nIcd translocates to the nucleus where it interacts with the cSL transcription factor 
to activate the notch target genes such as HeS, HeY, as well as eMT transcription 
factors such as Snail1 and Snail2 (High et al., 2007; Leong et al., 2007; niessen et al., 
2008; Pannuti et al., 2010). A relationship between overexpression of notch signaling 
and poor overall survival in breast cancer patients has been reported (Reedijk et al., 
2005). Interestingly, notch directly promotes Snail1 activation during hypoxia through 
the binding of its processed intracellular form to the Snail promoter and the activation of 
Lox2 expression by the hypoxia factor 1 (HIF-1), thereby stabilizing the Snail1 protein 
(Sahlgren	et	 al.,	 2008).	However,	unlike	 the	TGF-β	and	Wnt	pathways,	 activation	of	
the notch signaling pathway is not conserved among all the eMT processes during the 
course of embryogenesis and therefore may require other coordinating signaling inputs 
in order to promote an eMT.
In addition, multiple tyrosine kinase receptor pathways, including FGFR, eGFR, 
PdGFR, IGFR, HGFR and their ligands, can induce the expression of Snail, Slug and 
Zeb in tumor cells via crosstalk with other major signaling pathways, leading to their 
rapid induction and execution of the eMT program (Grotegut et al., 2006; Thiery et al., 
2009).	In	the	tumor	environment,	the	inflammatory	cytokines	(TNF-α,	IL-6,	LPS)	and	
reactive	oxygen	species	(ROS)	under	oxidative	stress	or	hypoxia	can	induce	the	NFκB	
pathway (Huber et al., 2004), which activates the expression of potent eMT inducers 
(Julien et al., 2007; Strippoli et al., 2008; Wu and Zhou, 2008). Recent studies have 
established the role of microRnAs in regulating eMT inducers (cano and nieto, 2008; 
Gibbons et al., 2009; Huang et al., 2008; Ma et al., 2007). A regulatory cascade involving 
microRNAs	and	EMT	transcriptional	regulators	 is	 likely	to	contribute	significantly	to	
the progression of many human cancers (Burk et al., 2008).
2.2. Cancer-associated Fibroblasts
Fibroblasts are associated with cancer cells at all stages of cancer progression, and the 
‘activated’	 fibroblasts	 within	 the	 tumor	 stroma	 have	 been	 termed	 cancer-associated	
fibroblast	(CAFs),	which	often	acquire	phenotypes	including	the	production	of	growth	
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factors, chemokines and extracellular matrix to facilitate the angiogenic recruitment of 
endothelial cells and pericytes into tumor stroma regions (Liotta and Kohn, 2001). cAFs 
are therefore a key determinant in the malignant progression of cancer and are attracting 
increasing attention both as recipients and as producers of pro-tumorigenic signals.
Although	 there	 are	 diverse	 subtypes	 of	 CAFs	 in	 different	 tumor	 types	 with	 specific	
functions, currently cAFs are mainly characterized based on morphological 
characteristics or the expression of a combination of different markers such as a-smooth-
muscle actin (aSMA),	vimentin,	desmin,	fibroblast-activated	protein	(FAP),	fibroblast-
specific	protein-1	(FSP1/S100A4),	neuron-glial	antigen-2	(NG2)	and	PDGFbeta	receptor	
(PdGFR-b).	Recent	CAF	gene	expression	profiling	analysis	have	identified	a	series	of	
novel markers including cell surface proteins, secreted growth factors and extracellular 
matrix proteins (Yang et al., 2008). experimental data indicate that cultured cAFs, due 
to genetic or epigenetic alterations, retain at least partially these phenotypic features 
during in vitro culture in the absence of tumor cells (de Wever et al., 2008; Garin-chesa 
et al., 1990; Ronnov-Jessen et al., 1996).
Local	 fibroblasts	 or	 fibroblast	 precursors	 in	 tumor	 stroma	 regions,	 stimulated	 by	 the	
PdGF or TGF-b family members, have generally been considered as the major source of 
cAFs (Hagood et al., 2005; Kalluri and Zeisberg, 2006; Koumas et al., 2003). However, 
recent studies have suggested that cAFs can also be derived from malignant or normal 
epithelial cells via the eMT process (Thiery, 2003; Thiery et al., 2010). endothelial cells 
undergoing	EndMT	were	recently	identified	as	another	source	of	CAFs,	expressing	both	
endothelial marker (cd31) and cAF markers (aSMA or FSP1) in experimental tumor 
model systems (di Tommaso et al., 2003).  Besides	EMT/EndMT	origin,	host	fibroblasts	
or bone marrow-derived cells can be recruited into the developing tumor region as an 
additional source of cAFs, altering the tumor microenvironment by several means, e.g. 
by	secreting	paracrine	factors	or	directly	influencing	the	behavior	of	many	different	cell	
types within the tumor (direkze et al., 2004; Ishii et al., 2003).
Activated cAFs can upregulate the expression of metalloproteinases (MMPs) and other 
extracellular matrix (ecM)-degrading proteases (Boire et al., 2005; Mackie et al., 1987; 
Sternlicht et al., 1999; Stetler-Stevenson et al., 1993) to allow cancer cells crossing tissue 
boundaries and escaping the primary tumor site. Additionally, cAFs express a range of 
growth factors and cytokines to stimulate tumor cell survival, proliferation, migration 
and invasion (ostman and Augsten, 2009). The tumor promoting activities of cAFs have 
best	been	defined	by	transplantation	of	CAFs	admixed	with	cancer	cells	into	mice,	and	
more recently by genetic and pharmacologic perturbation of their functions in tumor-
prone mice (Rasanen and Vaheri, 2010).
2.3.	 Inflammatory	and	immune	cells
The	abundance	of	inflammatory	and	immune	cells	in	tumor	tissue	was	observed	a	long	
time	ago,	and	these	cells	have	been	revealed	to	play	conflicting	roles	in	tumor	initiation,	
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progression	 and	metastasis.	Although	 immunologists	 have	 confirmed	 the	 presence	 of	
tumor-antagonizing	inflammatory	and	immune	cells	such	as	Cytotoxic	T	Lymphocytes	
(cTL) and natural-killer cells (nK), in most if not all neoplastic lesions, evidence 
has	accumulated	in	the	last	two	decades	demonstrating	that	the	regional	infiltration	of 
immune	or	inflammatory	cells	may	serve	to	promote	tumor	progression	(Grivennikov	
et	al.,	2006;	Karin	et	al.,	2006).	The	balance	between	conflicting	 tumor-antagonizing	
and	 tumor-promoting	 immune/inflammatory	 responses	 in	 tumors	 is	 likely	 to	 prove	
instrumental in prognosis and, quite possibly, in therapies designed to redirect these 
cells toward tumor destruction.
cancer cells overexpress a variety of growth factors such as granulocyte colony-
stimulating factor (G-cSF), granulocyte–macrophage colony-stimulating factor (GM-
cSF), and colony-stimulating factor 1 (cSF1) that recruit haematopoietic cells such as 
lymphocytes, monocytes (macrophages), and neutrophils into the tumor vicinity. The 
list	 of	 tumor-promoting	 inflammatory	 cells	 now	 contains	 subtypes	 of	 ‘alternatively	
activated’ macrophages, mast cells, neutrophils, as well as T and B lymphocytes that 
are normally engaged in wound healing and tissue regeneration. These cells can express 
diverse effector molecules to sustain tumor angiogenesis, to stimulate cancer cell 
proliferation, to facilitate tissue invasion, and to support the metastatic dissemination 
and seeding of cancer cells (coffelt et al., 2010; egeblad et al., 2010; Mantovani, 
2010; Murdoch et al., 2008; Qian and Pollard, 2010). In addition, subclasses of B 
and T lymphocytes may facilitate the recruitment, activation, and persistence of such 
tumor-promoting macrophages and neutrophils (Biswas and Mantovani, 2010; denardo 
et al., 2010; egeblad et al., 2010). Interestingly, a variety of partially differentiated 
myeloid	progenitors	have	been	identified	in	stroma	regions	(Murdoch	et	al.,	2008)	with	
demonstrable tumor-promoting activity. of particular interest, certain myeloid cells 
may	help	to	evade	immune	destruction	of	tumors,	indicated	by	identification	of	tumor-
infiltrating	CD11b+	Gr1+	myeloid	cells	capable	of	suppressing	CTL	and	NK	cell	activity	
(ostrand-Rosenberg and Sinha, 2009; Qian and Pollard, 2010).
2.4. Cancer Stem Cells
In	 recent	 years,	 evidence	 has	 accumulated	 pointing	 to	 the	 existence	 of	 a	 specific	
subpopulation of tumor cells possessing stem cell properties, termed cancer stem cells 
(CSCs).	CSCs	were	initially	identified	in	hematopoietic	malignancies	(Bonnet	and	Dick,	
1997; Reya et al., 2001) and later in some solid tumors, in particular breast carcinomas 
and neuroectodermal tumors (Al-Hajj et al., 2003; Gilbertson and Rich, 2007), which 
share	transcriptional	profiles	with	normal	stem	cells	in	the	tissue-of	origin,	motivating	
their designation as stem-like (creighton et al., 2009; Singh and Settleman, 2010). cScs 
could arise from existing stem/progenitor cells or from dedifferentiation of terminal 
differentiated cells into a primitive stem cell-like state. Recent research has connected 
the eMT transdifferentiation program with the acquisition of cSc traits. Studies indicate 
that immortalized human mammary epithelial cells that have undergone eMT driven 
28 Review of the Literature 
by	TGF-β	 treatment	or	by	 forced	expression	of	E-cadherin	 transcriptional	 repressors,	
such as Snail, give rise to a cd44high, cd24low cSc-like population (Mani et al., 
2008; Morel et al., 2008; Singh and Settleman, 2010). These eMT-induced cancer stem 
cells are proposed to become migratory in the circulation and revert into a differentiated 
phenotype when they arrive at a suitable distant organ, seeding the bulk of secondary 
tumor mass (Brabletz et al., 2005). 
2.5. angiogenesis and lymphangiogenesis
In	order	to	meet	increasing	needs	of	oxygen	and	nutrients	as	well	as	efficiently	remove	
metabolic wastes, normally quiescent vasculature gets angiogenically activated to 
continuously sprout new vessels during tumor growth (Hanahan and Folkman, 1996). 
new blood-vessel formation, maturation and recruitment of perivascular cells will 
continue	as	long	as	the	tumor	grows,	and	the	blood	vessels	specifically	feed	hypoxic	and	
necrotic areas of the tumor to provide it with essential nutrients and oxygen. eventually, 
the	sustained	angiogenesis	leads	to	a	high	number	of	leaky	blood	vessels	infiltrating	the	
tumor tissue, promoting not only tumor growth, but also progression from a premalignant 
to a malignant and invasive tumor phenotype (Mueller and Fusenig, 2004).
A compelling variety of evidence indicates that angiogenesis is orchestrated by 
countervailing factors that either activate or inhibit this process (Baeriswyl and 
christofori, 2009; Bergers and Benjamin, 2003). The stimulatory angiogenic regulators 
are mostly receptor tyrosine kinase ligands (carmeliet and Jain, 2000), such as VeGF, 
fibroblast	growth	factors	(FGF),	PDGF	and	epidermal	growth	factor	(EGF)	(Baeriswyl	
and christofori, 2009). Among these signaling pathways, VeGF ligands (VeGF-A, 
VeGF-c and VeGF-d) are well known to regulate the growth of new blood vessels via 
three receptor tyrosine kinases (VeGFR1-3) at multiple levels (Hanahan and Folkman, 
1996).
In contrast to capillary blood vessels, lymphatic capillaries are lined by a single layer of 
terminal differentiated Lecs, which have poorly developed junctions with frequent large 
inter-endothelial	gaps.	A	number	of	lymphatic	endothelium-specific	markers	have	been	
discovered including the prospero-related homeodomain transcription factor Prox1, 
the membrane glycoprotein podoplanin, vascular endothelial growth factor receptor-3 
(VeGFR-3), and lymphatic vessel hyaluronan receptor-1 (LYVe-1). However, Lecs 
also express blood endothelium markers such as von Willebrand factor (vWF) and 
cd31 (platelet/endothelial cell adhesion molecule 1, PecAM1) (dejana et al., 2009). 
The	main	function	of	lymphatic	vasculature	is	to	drain	interstitial	fluid	from	tissues	and	
returns it to the blood circulation. Lymphatic vessels are also an essential component 
of the immune system, and play important roles in the pathogenesis of lymphoedema, 
cancer	and	a	number	of	immune/	inflammatory	diseases	(Schulte-Merker	et	al.,	2011).	
Similar to angiogenesis, lymphangiogenesis is de novo lymphatic formation from 
pre-existing lymphatic vessels. Lymphangiogenesis can be induced by VeGF-c/d 
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and their receptor VeGFR-3. The VeGF-c/d coreceptor neuropilin-2 (nrp2) and the 
Eph4	tyrosine	kinase	ligand	ephrinB2	are	required	for	efficient	sprouting	of	lymphatic	
capillaries (Tammela and Alitalo, 2010). Although VeGF-c and VeGF-d also activate 
VeGFR-2 and thus induce angiogenesis, another VeGFR-2 activator, VeGF-A, cannot 
substitute	for	VEGF-C/D	in	promoting	efficient	lymphatic	sprouting	unless	the	Notch	
pathway activity is inhibited (Alitalo et al., 2005; Ridgway et al., 2006; Zheng et al., 
2011). Tumor lymphangiogenesis is thought to be correlated with the formation of 
metastasis in regional lymph nodes. A number of reports have recently described a 
significant	link	between	the	levels	of	the	lymphangiogenic	factor	VEGF-C	in	primary	
tumors and lymph node metastases. Larger lymphatics have been found surrounding 
the	VEGF-C	 overexpressing	 tumors,	which	may	 be	 sufficient	 to	 increase	metastasis,	
although the respective roles of lymphangiogenesis and lymphatic hyperplasia in tumor 
dissemination need to be explored in the future (Mumprecht and detmar, 2009; Pepper, 
2001; Stacker and Achen, 2008).
2.6. Matrix metalloproteinases
Matrix metalloproteinases (MMPs) are a family of zinc-dependent enzymes that were 
initially	 identified	 as	 the	 ECM	 cleaver	 but	 have	 subsequently	 been	 found	 to	 closely	
associate with many changes in the microenvironment during tumor progression 
(Kessenbrock et al., 2010). Based on the differential domain structure, MMPs can be 
principally divided into secreted (MMP-1, -2, -3, -7, -8, -9, -10, -11, -12, -13, -19,-20, 
-21, -22, -27, -28) and membrane-anchored proteinases (MT1-MMP to MT6-MMP, also 
called MMP-14, -15,-16, -17, -23, -24, -25, respectively) (Kessenbrock et al., 2010). The 
activity of MMPs depends on the local balance between them and their physiological 
inhibitors. The most important physiological inhibitors of MMP activity are tissue 
inhibitors of metalloproteinases (TIMPs), which are also commonly expressed in tumor 
sites (deryugina and Quigley, 2006), forming 1:1 stochiometric complexes with active 
MMPs and thus inhibiting their proteolytic activity. The different types of stromal cells 
produce	a	specific	set	of	proteinases	and	proteinase	inhibitors,	which	are	released	into	the	
extracellular space and create diverse protease activities in the tumor microenvironment 
(Ardi et al., 2007).
Almost all stages of tumor progression and metastasis are modulated by MMPs and other 
extracellular	proteinases,	mainly	provided	by	non-malignant,	 infiltrating	stromal	cells	
such	as	neutrophils,	macrophages,	fibroblasts	or	endothelial	cells	(Kessenbrock	et	al.,	
2010). during tumor invasion, cancer cell intravasation into blood vessels and the egress 
of metastatic tumor cells into the circulation, MMPs remodel the composition of the ecM 
by degrading the basement membrane and other ecM proteins, or downregulate cell 
adhesion molecules, such as cd44 or e-cadherin (Radisky, 2005; Yu and Stamenkovic, 
2000), thereby acting to support tumor progression. elevated levels of MMPs in the 
tumor microenvironment can directly induce eMT in epithelial cells (Billottet et al., 
2008; Radisky et al., 2005). Furthermore, eMT can generate activated stromal-like cells 
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that drive cancer progression via further MMP production. Studies of MMP localization 
in human tumors have shown that tumor progression and poor prognosis are associated 
with stromal expression of MMP-1, MMP-7, and MMP-12 (Finak et al., 2008), and with 
fibroblast-specific	production	of	MMP-9,	MMP-11,	and	MT1-MMP	(Del	Casar	et	al.,	
2009; Vizoso et al., 2007). Although extracellular proteolysis is mostly implicated in 
cancer promotion, MMPs also exhibit tumor-suppressing effects in several circumstances. 
For instance, angiogenesis can be triggered by the release of pro-angiogenic factors such 
as VeGF, which is mainly cleaved by MMP9 to release the active product (Bergers 
et	al.,	2000),	suggesting	a	beneficial	effect	of	MMP	inhibitors	on	tumor	angiogenesis.	
However, in other cancer models, MMP-9 provides anti-angiogenic signals, resulting in 
increased	tumor	growth	in	MMP-9-deficient	mice	(Hamano	et	al.,	2003).	This	illustrates	
that the same MMP can have opposing effects in different tumor types and underscores 
a	careful	evaluation	of	MMP	inhibitors	for	each	specific	kind	of	cancer.
Similar to other MT-MMPs, proMT1-MMP (64 kda) is converted to a catalytically 
active MT1-MMP enzyme (55 kda) by proteolytic cleavage by furin in the trans-Golgi 
network prior to its arrival at the plasma membrane (Mazzone et al., 2004; Yana and 
Weiss, 2000). Activation of the secreted MMPs is mediated by a cell-surface complex that 
consists of a homodimer of MT1-MMP as well as a single molecule of tissue inhibitor of 
metalloproteinases-2 (TIMP-2; a natural inhibitor of MMPs) (Itoh et al., 2001; Strongin 
et al., 1995). In addition, MT1-MMP also directly cleaves ecM components including 
collagen,	 gelatin,	 laminins	 1	 and	 5,	 fibronectin,	 vitronectin,	 aggrecan	 and	fibrin,	 and	
cell-surface	proteins	 such	as	CD44,	αV	 integrins	and	syndecan	1	 (Overall	 and	Dean,	
2006). MT1-MMP promotes tumor progression and metastasis (deryugina and Quigley, 
2006;	Hofmann	et	al.,	2005)	as	well	as	tumor	growth	and	local	invasion	in	a	confined	
three-dimensional (3d) ecM environment (Hotary et al., 2003; Lehti et al., 2009). 
Intriguingly, MT1-MMP was shown to accumulate at the invasive front of tumors 
(Hofmann et al., 2003; Ueno et al., 1997) and to be enriched at invadopodia, facilitating 
matrix degradation (Bowden et al., 1999; Buccione et al., 2004; clark and Weaver, 
2008; Gimona et al., 2008). Indeed, poor prognosis of eMT-driven tumor progression 
is	 associated	with	 fibroblast-specific	 production	 of	MT1-MMP	 (Vizoso	 et	 al.,	 2007).	
Furthermore, MT1-MMP contributes to tumor angiogenesis via various mechanisms, 
including activation of avb3-integrin (which protects endothelial cells from apoptosis), 
fibrinolytic	 activity,	 MMP-2	 activation	 and	 the	 transcriptional	 regulation	 of	 VEGF	
expression (Mu et al., 2002; Tatti et al., 2008). MT1-MMP	has	also	been	identified	as	
a	novel	proteolytic	modifier	of	PDGFR-b signaling pathway in regulating vessel wall 
architecture (Lehti et al., 2005). 
3. Kaposi’s sarcoma herpesvirus (KSHV)
Gammaherpesviriae family consists of two subfamilies called Lymphocryptovirus 
(e.g., eBV) and Rhadinovirus (e.g., KSHV) (cesarman et al., 1995a). Kaposi’s 
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sarcoma herpesvirus (KSHV), also known as human herpesvirus-8 (HHV-8), was 
identified	in	1994	from	Kaposi’s	sarcoma	biopsies	through	representational	difference	
analysis (chang et al., 1994). KSHV is a double-stranded dnA virus, representing an 
etiological agent of three types of malignancies: Kaposi’s sarcoma (KS), Multicentric 
castelman disease (Mcd), and B cell primary effusion lymphoma (PeL) (Ablashi et 
al., 2002). 
3.1. KSHV-associated malignancies
Most of sub-Saharan Africa regions have more than 50% overall seroprevalence 
rates of KSHV infection, followed by the Mediterranean region with an intermediate 
seroprevalence rate of 10–30%. The KSHV seroprevalence in northern europe, Asia 
and the United States is usually quite low, with less than 10% rates (Mesri et al., 2010).
3.1.1. Kaposi’s sarcoma (KS)
In 1872, the Hungarian doctor Moritz Kaposi found a new type of skin neoplasms 
consisting of red and purple plaques or nodules described as the term “sarcoma”, 
indicating the similarities between this disease and traditional mesenchymal tumors. 
According	 to	 epidemiologic	 distinctions,	KS	 has	 been	 classified	 into	 four	 different	
types. classic KS is usually an indolent disorder in Mediterranean elderly men, 
with no link to HIV infection (diGiovanna and Safai, 1981). The lesions progress 
slowly	 and	 are	 generally	 confined	 to	 the	 skin,	 rarely	 threatening	 life.	 Endemic	KS	
is a more aggressive disease than classic KS, affecting HIV negative sub-Saharan 
Africans (Bayley, 1984; Stein et al., 1994; Taylor et al., 1971). Iatrogenic KS involves 
immunosuppressed patients undergoing solid-organ transplantation (cattani et 
al., 2000; Farge, 1993; Farge et al., 1999; Margolius et al., 1994; Parravicini et al., 
1997; Qunibi et al., 1998; Shepherd et al., 1997). The most common type of KS is 
AIdS-associated KS, also called “epidemic” KS, which is a highly aggressive and 
disseminated cutaneous malignancy. The early stage of KS lesions on the skin is often 
the	 first	 and	most	 common	 symptom	 in	AIDS	 patients,	 especially	 amongst	 the	 the	
homosexual population. These lesions can spread to large areas of the body surface, 
sometimes in a symmetrical fashion. Advanced complications involve the oral mucosa 
and visceral organs including the gastrointestinal tract and lungs, leading to life-
threatening gastrointestinal bleeding or respiratory failure (Beral et al., 1990; Biggar 
and Rabkin, 1996; Hermans et al., 1998).
KS lesions are composed of a remarkable diversity of cell types, which are different 
from histologically monotonous clonal outgrowths of a single cell type in most cancers 
(Grayson and Pantanowitz, 2008; Herndier and Ganem, 2001). early-stage patch KS 
lesions	are	composed	of	elongated,	spindle-shaped	cells	accompanied	by	an	infiltration	
of	inflammatory	cells	(T	and	B	cells,	monocytes).	Prior	to	establishment	of	recognizable	
tumor mass, abundant neovascularity has been prominent at this stage, making the 
lesions reddish to the naked eye. As the lesions progress to the plaque stage, the vascular 
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process expands through the skin to form intense red or even violacerous color. With the 
continuous proliferation of spindle cells, late nodular stage KS is composed of prominent 
multiple layers of spindle cells and slit-like neovascular spaces, accompanied again by 
inflammatory	cells	(Ganem,	2010).
Spindle cells are the primary infected cell type in KS lesions and are considered to be the 
tumor cells of KS (Boshoff et al., 1995). These cells bear many markers of the endothelial 
lineage, including cd31, cd34, cd36, and factor XIII (Rutgers et al., 1986). However, 
the endothelial origin of these cells is not conclusive due to the heterogeneous pattern of 
marker	expression,	such	as	those	of	smooth	muscle	cells	and	fibroblasts,	by	the	spindle	
cells, suggesting a potential mesenchymal origin of these cells (Ganem, 2010). Lymphatic 
makers (e.g., podoplanin and LYVe-1) as well as the lymphangiogenetic factor VeGF-c 
and its receptor VeGFR-3 were found to be expressed on spindle cells, indicating that 
they could be derived from a lymphatic rather than vascular endothelium (Marchio et al., 
1999; Skobe et al., 1999; Weninger et al., 1999). Interestingly, global gene expression 
analyses have demonstrated that the KS gene expression signature resembles more 
that of Lecs than blood endothelial cells (Becs). KSHV can drive Becs to shift their 
gene expression towards a lymphatic lineage, while infected Lecs alter transcriptional 
patterns toward vascular endothelium, indicating a role of transcriptional reprogramming 
to explain the pleiotropy of marker expression in spindle cells (carroll et al., 2004; Hong 
et al., 2004; Wang et al., 2004a).
Another histological complexity of KS is the occurrence of multifocal lesions, which 
often arise independently (multicentricity) from a primary lesion (Brooks, 1986). 
Molecular	analysis	of	multiple	KS	lesions	confirms	the	genomic	differences	of	KSHV	
in different lesions, suggesting that they arise from independent infection events 
(Duprez	et	al.,	2007).	In	addition,	the	inflammatory	microenvironment	constitutes	an	
important	part	of	KS	histology.	Spindle	cells	in	KS	lesions	produce	cytokines	(IFN-γ,	
TnF-a, IL-1, IL-6), chemokines (McP-1, IL-8), angiogenic factors (FGF, VeGF, 
PDGF),	and	display	upregulation	of	TGF-β,	PDGF-β,	CCR5	as	well	as	their	receptors,	
which	 provide	 proinflammatory	 factors,	 proangiogenic	 factors,	 growth	 factors	 and	
other substances necessary for spindle cell survival and proliferation (Mesri et al., 
2010).
3.1.2. primary effusion lymphoma (pEl) and other KSHV-induced disorders
After the discovery of KSHV in 1994, PeL was recognized as a unique type of diffuse 
large B-cell lymphoma commonly found in AIdS associated KS patients as well as 
HIV negative organ-transplantation patients (Ansari et al., 1996; carbone et al., 1996; 
cesarman et al., 1995a; nador et al., 1996). This type of malignant lymphoma is caused 
by KSHV, and in most cases, the lymphoma cells are co-infected with eBV, suggesting 
that eBV could be an important pathogenic co-factor (cesarman et al., 1995b; nador 
et al., 1996). As a rare, aggressive (fast-growing) type of non-Hodgkin lymphoma, 
PeL tumors consist of a malignant counterpart of B-cells that have matured but have 
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not undergone terminal plasma cell differentiation (carbone et al., 1997; Gaidano et 
al., 1996). PeL is also called “body cavity lymphoma” since the majority of cases arise 
in body cavities, such as the peritoneal, pericardial or pleural space to form malignant 
effusions without associated solid tumor masses. during the advanced stages of PeL, 
accumulation of the effusions in certain body cavities cause serious symptoms such 
as dyspnea (due to pleural or pericardial effusion) or abdominal swelling (due to 
peritoneal effusion),  with the majority of the patients dying within a few months 
(Boulanger et al., 2003; Boulanger et al., 2005; Boulanger et al., 2004; Waddington 
and	Aboulafia,	2004).
Mcd is a very rare disorder characterized by hyperproliferation of certain types of 
lymphocytes in multiple lymphatic tissues throughout the body. More than 50% of 
Mcd cases are associated with KSHV, while the remaining KSHV negative cases are 
in hyaline-vascular form of unknown cause (casper, 2005; dupin et al., 1999; Gessain 
et	al.,	1996;	Soulier	et	al.,	1995).	MCD	progresses	rapidly	and	is	difficult	to	diagnose.	
even in the case of a lymph-node biopsy a conclusive diagnosis remains problematic. 
The most common symptoms of Mcd are high fever, anemia, weight loss, low white 
blood cell counts, lymphadenopathy, and dyspnea, causing high fatality of the patients 
(oksenhendler et al., 1996).
3.2. KSHV life cycle
The linear, double-stranded KSHV dnA of approximately 165 kilobases (kb) in the 
viral capsid circularizes into a closed episome in the nucleus of the host cell upon 
infection. 140 kb of this dnA contains at least 87 open reading frames (oRFs), 
flanked	on	each	side	by	multiple	801-base	pair	(bp)	terminal	repeat	units	(TR)	(Wen	
and damania, 2010) (see Figure 3). As with other herpesviruses, infection by KSHV 
displays two life cycle phases known as latency and lytic replication. during latency 
KSHV persists as extrachromosomal episomal dnA with only few viral genes 
expressed, while during lytic replication the virus is reactivated with initiation of 
extensive viral dnA replication and gene expression, resulting in production of new 
viral particles and contributing to KSHV pathobiology (Mesri et al., 2010; Miller et 
al., 1997; Renne et al., 1996).
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Figure 3. The genome of KSHV with indicated latent and lytic genes. KSHV genome exists 
as an episome (double-stranded circular dnA) within the host nucleus and it encodes 87 oRFs 
as well as at least 17 microRnAs, 14 of which are co-expressed as a cluster. Putative latent 
oRFs and encoded proteins are indicated in green boxes, microRnA clusters are indicated in 
purple boxes, and lytic genes/encoded proteins mentioned in this thesis are indicated in red boxes. 
TR	(blue	box)	denotes	 terminal	 repeats	of	 the	genome	(Adapted	and	Modified	from	Wen	and	
damania 2010).
3.2.1. latency and lytic cycle
during latent infection, KSHV expresses only a minority of the nearly 100 genes in the 
genome (Zhong et al., 1996). Among these are genes encoding latency-associated nuclear 
antigen (LAnA), viral cyclin (v-cyclin), and anti-apoptotic viral FLIce-inhibitory 
protein (vFLIP), which are translated from a common polycistronic transcriptional unit 
called the latency transcript (LT) cluster (dittmer et al., 1998; Sarid et al., 1998; Talbot 
et al., 1999). Viral interleukin-6 (vIL-6), which was regarded as a lytic gene, has recently 
been	demonstrated	as	a	bone	fide	latent	protein	in	primary	effusion	lymphoma	(PEL)	
cells, supporting PeL growth and survival in an autocrine manner (chen et al., 2009). 
In addition, other later genes expressed in the latent phase include Kaposin (Muralidhar 
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et al., 1998; Sadler et al., 1999), viral interferon regulatory factor 3 (vIRF3, LAnA2) 
(Lubyova and Pitha, 2000) and a recently discoved microRnA cluster (See also in Figure 
3) (cai et al., 2005; Pfeffer et al., 2005; Samols et al., 2005).
The switch from latent infection to lytic replication is called viral reactivation. Several 
chemicals such as protein kinase c agonists, histone deacetylase (HdAc) inhibitors, 
phorbol esters, dnA methyltransferase inhibitors or physiological stimuli such as 
hypoxia can trigger the reactivation program, after which the viral lytic genes start to 
be expressed in an orderly pattern (immediate early/Ie, delayed early/de and late/L) 
based on their temporal expression kinetics, leading to the production of infectious 
virions (See also in Figure 3) (chen et al., 2001; davis et al., 2001; Miller et al., 1997; 
Renne et al., 1996; Vieira et al., 2001). expression of immediate early (Ie) lytic genes is 
activated upon primary infection or reactivation from latency. delayed early (de) genes 
are expressed after the Ie, but prior to viral dnA synthesis, while late lytic genes, whose 
expression is inhibited by phosphonoacetic acid or ganciclovir, usually appear after 30 
hours post-induction (Sun et al., 1999; Zhu and Yuan, 2003). The full execution of the 
lytic program results in additional replication of viral dnA, transcription of viral genes, 
translation of viral gene products, assembly and release of viral particles, causing the 
death of host cells (Lukac et al., 1999; Lukac et al., 1998; Sun et al., 1998).
3.2.2. laNa and latency maintenance
LAnA encoded by the open reading frame 73 (oRF73) of the KSHV genome is expressed 
in all KSHV-infected cells (Gao et al., 1996a; Kedes et al., 1997) and is a major protein 
expressed in KSHV latency. It is a protein of 1,162 amino acids, 222 to 234 kda in 
molecular size, containing an n-terminal domain rich in serine, threonine, proline, and 
basic residues, a highly polymorphic internal repeat domain and a c-terminal domain 
abundant in charged and hydrophobic residues (Gao et al., 1999; Zhang et al., 2000). 
As a multifunctional protein, LAnA can promote cell survival and regulates cell cycle 
progression by modulating various cellular targets, including p53, Rb, and Wnt pathways 
(An et al., 2005; Friborg et al., 1999; Fujimuro et al., 2003).
during latency, LAnA tethers the viral episomal dnA to the cellular mitotic 
chromosomes,	 appearing	 as	 typical	 nuclear	 spots	 upon	 indirect	 immunofluorescence	
with	 LANA-specific	 antibodies	 (Gao	 et	 al.,	 1996a;	 Gao	 et	 al.,	 1996b;	 Kedes	 et	 al.,	
1996).	Previous	studies	have	implied	that	the	C-terminus	of	LANA	binds	specifically	to	
sequences within the terminal repeat (TR) regions (Garber et al., 2001; Grundhoff and 
Ganem, 2003; Hu et al., 2002) of the KSHV episomal genome (Schwam et al., 2000; 
Verma et al., 2006; Viejo-Borbolla et al., 2005). Additionally, Both n- and c-terminal 
LAnA domains bind to host chromosomes, tethering episomes to the nucleosome during 
mitosis and interphase through interaction with core histones H2A and H2B (Barbera et 
al., 2004; Barbera et al., 2006; Krithivas et al., 2002; Piolot et al., 2001; Shinohara et 
al., 2002). of note, LAnA not only tethers the KSHV episome to the host chromosomes 
but also actively cooperates with a panel of chromosome-binding and origin recognition 
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complex (oRcs) proteins to facilitate viral episomal replication (Stedman et al., 2004; 
Stedman et al., 2008; Verma et al., 2006). In addition to its role in episomal maintenance 
and segregation, LAnA also acts as a transcriptional activator or repressor to modulate 
cellular and viral gene expression, helping to keep the virus in its latency cycle.
3.2.3. RTa and lytic reactivation
The best characterized Ie lytic gene is RTA (replication and transcription activator, a 
homologue of eBV RTA, also called oRF50), which serves as the molecular switch 
for the viral life cycle (Lukac et al., 1998; Sun et al., 1998). during latency, RTA 
expression	 is	 repressed	 through	 epigenetic	modifications.	 It	 has	 been	 suggested	 that	
dnA methylation and acetylation may regulate the transcription of the oRF50 gene 
through chromatin remodelling (Lu et al., 2003). Hypermethylation of the RTA promoter 
can suppress RTA protein expression as well as recruit transcriptional repressors and 
HdAcs in the promoter region (chen et al., 2001). In addition, KSHV latent protein 
LAnA can inhibit RTA transcription by suppressing its promoter (Lan et al., 2005a; Lan 
et	al.,	2004)	or	influencing	related	transcription	factors	(Lan	et	al.,	2005b;	Verma	et	al.,	
2004). For instance, by directly interacting with RBPJ (Recombining binding protein for 
immunoglobulin kappa J region), LAnA may not only recruit additional corepressors to 
suppress the transcription of the RTA gene, but also repress RTA autoactivation activity 
by competing with RTA in RBPJ-binding (Lan et al., 2005b; Verma et al., 2004).
Several	 lines	 of	 evidence	 demonstrate	 that	 RTA	 is	 both	 sufficient	 and	 necessary	 to	
mediate the switch from latency to lytic replication of KSHV. ectopic expression of 
RTA in latently infected cells can induce the expression of downstream lytic proteins and 
encapsidated viral dnA, suggesting that RTA alone is capable of initiating reactivation 
and driving the whole viral lytic cycle cascade (Gradoville et al., 2000; Lukac et al., 
1999; Sun et al., 1998). complete deletion of RTA or expression of a dominant-negative 
RTA mutant suppresses viral reactivation, further supporting the necessity of RTA in 
viral lytic reactivation (Lukac et al., 1999; Xu et al., 2005).
As the earliest lytic protein, RTA is able to transactivate a variety of downstream lytic 
genes to complete lytic replication cascade. The demonstrated RTA downstream targets 
include Ie genes such as K3 (chang et al., 2005a), K5 (Haque et al., 2000) and oRF45 
(Zhu et al., 1999), de genes such as K1 (Bowser et al., 2002; Bowser et al., 2006), K2/
vIL-6 (deng et al., 2002), K9/vIRF-1 (Ueda et al., 2002), K8 (Lukac et al., 1999), K15 
(Wong and damania, 2006), oRF57 (Lukac et al., 1999), ORF59(chan and chandran, 
2000) oRF74/vGPcR (Kirshner et al., 1999) and others, as well as late (L) lytic genes 
such as K8.1 (chandran et al., 1998) and ORF25 (Ascherl et al., 1999). The activation 
of these downstream genes is mediated through two distinctive strategies: RTA either 
directly recognizes RTA-responsive elements in the promoters of its target genes, or it 
interacts with cellular or viral factors already recruited to the promoters (chang et al., 
2005a; chang et al., 2005d; Song et al., 2003). As a potent transcriptional activator, 
RTA protein can also activate the oRF50 gene itself, representing a critical way for 
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KSHV	to	efficiently	respond	to	environmental	stimuli	and	maximally	activate	the	virus	
lytic cycle. A 3-kb fragment of RTA promoter is shown to be highly responsive to the 
lytic inducing chemical  12-o-tetradecanoyl-phorbol-13-acetate (TPA), sodium byturate 
(naB) as well as RTA itself (deng et al., 2000; Gradoville et al., 2000). Upon a luciferase 
reporter assay, the RTA response element (RRe) on the RTA promoter was mapped to 
an octamer-binding site, bound by cellular oct1 protein in an electrophoretic mobility 
shift assay (eMSA) (Sakakibara et al., 2001). RBPJ, a known cellular partner of RTA 
(Liang et al., 2002), is also involved in the autoactivation of RTA promoter. chang et al. 
have shown that the RTA promoter with multiple RBPJ-binding sites was autoactivated 
at a higher level than that lacking RBPJ-binding sites (chang et al., 2005a). These lines 
of evidence suggested that autostimulation of the RTA promoter is mediated by the RTA 
protein and at least two cellular proteins, RBPJ and oct-1.
3.2.4. involvement of host cellular signaling pathways in KSHV reactivation
A variety of cellular signaling pathways have been shown to regulate KSHV reactivation. 
As discussed before, RBPJ, the primary target of notch signaling, mediates RTA-
dependent activation of KSHV lytic genes via binding to multiple RBPJ-binding sites 
on the RTA promoter and on multiple RTA target promoters, such as oRF57, TK, K14/
vGPcR, RTA, K3, K5, vIL-6, and vMIP-1 (Liang et al., 2002). Indeed, in an RBPJ-
knockout cell line (Liang and Ganem, 2003), KSHV can still establish latency but 
RTA-induced lytic reactivation is completely abolished, probably due to the defective 
expression of multiple lytic genes that depend on RBPJ for activation by RTA. Three 
MAPK pathways (MeK/eRK, MeK/JnK, and p38 MAP kinase pathways) have been 
shown to mediate the latent-lytic switch (cohen et al., 2006; Ford et al., 2006; Pan et 
al., 2006) through activation of the transcriptional factor AP-1, which associates with 
the RTA promoter, leading to expression of RTA protein, and to activation of the lytic 
program (Xie et al., 2008). Moreover, dopamine receptors were reported to be associated 
with MAPK pathways to detect and transmit favorable stress signals for viral reactivation 
(Lee et al., 2008). Recently a functional genome-wide cdnA library (containing twenty-
six thousand mammalian genes) screen was conducted to systematically evaluate the 
cellular signals regulating KSHV life cycle through a luciferase reporter system. In the 
screen,	the	Raf/MEK/ERK/Ets-1	pathway	was	identified	to	mediate	Ras-induced	KSHV	
reactivation (Yu et al., 2007b). 
The	role	of	the	NF-κB	pathway	in	KSHV	lytic	replication	remains	controversial.	In	PEL	
cells,	inhibition	of	NF-κB	led	to	KSHV	reactivation	and	the	expression	of	lytic	proteins	
(Brown	et	al.,	2003),	however,	it	was	reported	that	NF-κB	induction	was	required	for	
the production of KSHV infectious virions in PeL cells induced for reactivation by TPA 
(Sgarbanti	et	al.,	2004).	Recently,	PI3K-Akt	pathway	has	been	identified	as	a	negative	
regulator as inhibition of this pathway enhanced KSHV lytic replication and facilitated 
reactivation from latency (Peng et al., 2010). 
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Several host factors have been found to regulate the latent-lytic switch via remodeling of 
the RTA promoter. For instance, the chromatin-remodeling complex SWI/SnF and the 
TRAP/mediator coactivator can be recruited downstream of the RTA promoter, which is 
essential for RTA-dependent viral gene expression (Gwack et al., 2003). Furthermore, 
two	transcription	factors,	the	CCAAT/enhancer-binding	protein-α	(C/EBPα)	(Landschulz	
et al., 1988; Wang et al., 2003) and the X-box binding protein 1 (Wilson et al., 2007; 
Yu et al., 2007a) have been shown to transactivate the RTA promoter and enhance lytic 
reactivation.
3.2.5. Chemical and physiological inducers of KSHV reactivation
Viral reactivation can be induced in cell culture by the addition of a number of chemical 
agents, providing valuable tools for studying cellular pathways that may be involved 
in KSHV reactivation. As the RTA promoter is associated with histone deacetylases 
in latent PeL cells, treatment with inhibitors of histone deacetylase (HdAc) such as 
naB (Boffa et al., 1978), or trichostatin A (TSA) can reverse the acetylation process 
of the RTA promoter and therefore induce KSHV reactivation (Lu et al., 2003). An 
histone acetyltransferases (HAT) inducer, TPA (Masumi et al., 1999) can also affect 
the acetylation status of the RTA promoter by activating a variety of transcriptional 
factors and enhancing their dnA-binding activity (Renne et al., 1996; Sarid et al., 1998; 
Wang et al., 2004b). Following the initial activation by naB, RTA can be recruited to 
its responsive elements through direct interaction with the notch signaling pathway 
transcription factor RBPJ (chang et al., 2005a; chang et al., 2005b; Liang and Ganem, 
2004) while TPA can activate the calcium-dependent calcineurin signaling pathway as 
well	as	the	protein	kinase	C	(PKC)	δ	pathway,	inducing	KSHV	reactivation	from	latency	
(deutsch et al., 2004; Zoeteweij et al., 2001). In addition, activation of the Ap-1 pathway 
has also been suggested to be involved in TPA-induced KSHV reactivation (Wang et al., 
2004b). Recently, it was reported that Ras/Raf/MeK/eRK/ets-1, JnK and p38 MAPK 
pathways also mediate TPA-induced KSHV reactivation from latency (Xie et al., 2008; 
Yu et al., 2007b). Induction of KSHV lytic replication has been reported in response to 
a variety of other chemicals such as ionomycin (Lukac et al., 1999) and 5-azacytidine 
(chen et al., 2001) via chromosomal modulation and enhancement of viral release.
The	immune	and	inflammatory	systems,	consisting	of	a	variety	of	cellular	elements	and	
humoral factors, are the initial host defense against viral pathogens. Several cytokines 
such	 as	 IL-6	 (Chang	 et	 al.,	 2000;	Chatterjee	 et	 al.,	 2002),	 IFN-γ	 (Blackbourn	 et	 al.,	
2000; chang et al., 2000; Mercader et al., 2000; Monini et al., 1999) and oncostatin 
M (Mercader et al., 2000) have been shown to induce KSHV reactivation, but the 
underlying	mechanisms	remain	undefined.	Several	neuron	transmitters	associated	with	
stress	 responses,	 such	 as	 epinephrine	 and	norepinephrine,	 could	 efficiently	 reactivate	
KSHV	from	latency	via	β-adrenergic	activation	of	the	protein	kinase	A	(PKA)	signaling	
pathway (chang et al., 2005c). The cellular IRF-7 was shown to be a negative regulator 
of KSHV lytic replication by competing with RTA for binding to the RTA-responsive 
element in the oRF57 promoter (Wang et al., 2005) and in turn RTA, by using its own 
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e3-ubiquitin ligase activity, targets IRF-7 for proteasome-mediated degradation (Yu et 
al., 2005). Hypoxia stress, which is usually a physiological stimulus rich in the KS tumor 
microenvironment, has also been found to reactivate KSHV, probably via cytokines such 
as IL-6 (Haque et al., 2003). Moreover, when cells are co-infected with KSHV and HIV, 
the HIV Tat protein may induce KSHV replication and increase KSHV viral load via 
JAK/STAT signaling (Zeng et al., 2007).
3.2.6. implications of lytic replication in KSHV pathogenesis
Although persistent KSHV infected cells are predominantly latent (Reed et al., 1998; 
Staskus et al., 1999; Staskus et al., 1997; Zhong et al., 1996), lytic replication has been 
suggested to play a key role in the development and progression of KSHV-induced 
malignancies. KSHV lytic genes such as vGPcR, vIL-6, vBcl-2, K1 and vIRF1 have 
been shown to have oncogenic potential in vitro and/or in vivo (Mesri et al., 2010). 
Indeed, the viral lytic replication is associated with KS malignancy as higher KSHV 
viral loads are usually detected in higher grade of clinical KS (Ganem, 2010). Moreover, 
another KSHV malignancy, Mcd, is characterized by a periodic KSHV lytic replication 
with high viremia in the peripheral blood (Katano et al., 2000; oksenhendler et al., 
2000). Therefore, an anti-viral treatment designed to abolish KSHV lytic replication 
may represent a therapeutic option in KSHV-induced malignancies.
So far, a couple of anti-herpetic dnA synthesis inhibitors have been developed against 
KSHV associated malignancies (naesens and de clercq, 2001). These inhibitors, either 
via phosphorylation by the herpesvirus thymidine kinase and by UL97 phosphotransferase 
(aciclovir and ganciclovir) or via an alternative mode of action (cidofovir and Foscarnet), 
are able to incorporate a nucleoside analogue into a growing viral dnA and thereby 
terminate the elongation of dnA synthesis (Mercorelli et al., 2008). A series of reports 
revealed promising therapeutic outcomes in PeL patients treated with ganciclovir or 
cidofovir alone or in combination with chemotherapy or Highly Active Anti-Retroviral 
Therapy	(HAART)	(Crum-Cianflone	et	al.,	2006;	Hocqueloux	et	al.,	2001;	Luppi	et	al.,	
2005; Pastore et al., 2000). Similar effects were also achieved in Mcd patients treated 
with ganciclovir (casper et al., 2004; Valencia et al., 2005), but not with cidofovir 
(Berezne et al., 2004). For those patients either intolerable or refractory to standard 
chemotherapies,	intracavitary	administration	of	cidofovir	together	with	adjuvant	IFN-α	
may turn out to be an alternative solution (Boulanger et al., 2003).
3.3. KSHV encodes several proteins with transforming capacity
KSHV is strongly associated with KS development since the KSHV dnA is found in 
spindle cell region in all KS lesions. These spindle cells are highly proliferative and 
thought to be the cells to drive KS pathogenesis (Boshoff et al., 1995; collandre et 
al., 1995; dupin, 1995). Moreover, KSHV infection precedes KS development and the 
seroprevalence of viruses predicts the KS risk as well as mirrors the frequency of clinical 
KS, implying that KSHV is the etiological agent necessary for KS tumorigenesis (Gao 
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et al., 1996b; Kedes et al., 1996; Martin et al., 1998; Simpson et al., 1996; Smith et al., 
1999).  So far, several KSHV encoded proteins, both latent and lytic, have shown their 
transforming capacity in cell culture and/or in mice.
3.3.1. laNa
In addition to its role in episomal maintenance, LAnA is one of the most important 
KSHV proteins contributing to tumorigenesis. For example, LAnA can physically 
associate with the tumor suppressors Rb as well as the bromodomain-containing protein 
RInG3/Brd2, thereby inhibiting apoptosis, deregulating the cell cycle and enhancing cell 
proliferation (denis et al., 2000; Friborg et al., 1999; Guo et al., 2000; Platt et al., 1999; 
Radkov et al., 2000; Viejo-Borbolla et al., 2005). However, overexpression of LAnA 
alone fails to initiate anchorage-independent growth of nIH3T3 cells, demonstrating the 
importance of other viral genes and factors for KSHV-induced malignancies (Watanabe 
et al., 2003). LAnA can also cooperate with H-Ras to transform primary rat embryo 
fibroblasts,	or	deregulate	oncogene	CCND1	and	Myc	expression	via	glycogen	synthase	
kinase (GSK)-3b/b-catenin signaling pathway (Boshoff, 2003; Fujimuro and Hayward, 
2003; Radkov et al., 2000). It also interacts with Sp1 transcription factor to mediate 
telomerase expression (Verma et al., 2004). 
LAnA has been found to interact with p53, inhibit p53 transcriptional activity and 
repress p53-dependent apoptosis (Friborg et al., 1999). LAnA could form a complex 
with p53 and mouse double minute protein 2 (MdM2), regulating ubiquitin e3-ligase 
activity of MdM2 towards p53 (chen et al., 2010; Sarek et al., 2007). Suppression of 
p53 activity by LAnA has also been linked with genomic instability (Si and Robertson, 
2006). Moreover, enhanced multinucleation, abnormal establishment of centrosomes, 
and creation of mitotic bridges are reported in mammalian cells with a stable expression 
of LAnA (Si and Robertson, 2006). Finally, transgenic mice expressing LAnA 
developed follicular hyperplasia with increased germinal centers in the spleen as well as 
lymphomas, further indicating its role in early stage of KS associated tumor development 
(Fakhari et al., 2006).
3.3.2. vFlip
The viral FLIce (Fas-associated death-domain like IL-1b-convertase enzyme) inhibitory 
protein (vFLIP) is a latent KSHV protein, which can inhibit Fas-mediated apoptosis 
through binding and prevention of procaspase-8 maturation, thus providing a survival 
advantage for infected cells (Belanger et al., 2001; djerbi et al., 1999). Additionally, 
vFLIP, in cooperation with cellular FLIP through their inhibitory interaction with the e2-
like enzyme, Atg3, effectively blocked cell death with autophagy, induced by rapamycin, 
an mToR inhibitor and an effective anti-tumour drug against KS and PeL (Lee et al., 
2009). Furthermore, vFLIP expression was shown to inhibit anoikis (detachment induced 
apoptosis) in primary dermal microvascular endothelial cells, partly by inducing the 
secretion of paracrine survival factors (efklidou et al., 2008). Similar to cellular FLIPs, 
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vFLIP	 also	 associates	with	 the	 Iκκ	 complex	 and	 the	 heat	 shock	 protein	 90	 (HSP90)	
to induce nF-kB survival signaling (chaudhary et al., 1999; Field et al., 2003). The 
enhanced	 NF-κB	 signaling	 may	 be	 important	 for	 the	 transforming	 and	 oncogenic	
potential	of	vFLIP	as	demonstrated	in	Rat-1	fibroblast	transformation	assays	and	growth	
of tumors in nude mice (Sun et al., 2003). A recent study showed that vFLIP cooperates 
with	c-Myc	to	elevate	NF-κB	activity,	to	decrease	in	apoptosis	and	to	promote	lymphoma	
in	vFLIP/iMyc(Eμ)	double	transgenic	mice,	confirming	its	oncogenic	capability	in vivo 
(Ahmad et al., 2010). Another recent report demonstrates that vFLIP increases levels of 
notch ligand JAG1 through an nF-kB dependent mechanism. notch activation elicits 
significant	suppression	of	the	expression	of	cell	cycle	components	in	adjacent	uninfected	
cells and may provide a growth advantage to KSHV infected cells over uninfected 
surrounding cells (emuss et al., 2009).
3.3.3. v-cyclin
The latent KSHV protein viral cyclin (v-cyclin) is a functional cyclin d homolog with an 
approximate molecular weight of 29 kda. The v-cyclin preferably binds to and activates 
cyclin-dependent kinase 6 (cdK6) and only weakly associates with cdK2, cdK3, 
cdK4, cdK5, and cdK9 (chang and Li, 2008; Godden-Kent et al., 1997; Li et al., 
1997; Platt et al., 2000). The v-cyclin-cdK kinase complex phosphorylates a broad 
range of substrates including histone H1 and Rb (Godden-Kent et al., 1997; Li et al., 
1997), p27KIP1 (ellis et al., 1999; Mann et al., 1999; Swanton et al., 1997), p21cIP1 
(Jarviluoma et al., 2006), Id-2 and cdc25a (Mann et al., 1999), cdc6 and oRc1 (Laman 
et al., 2001), Bcl-2 (ojala et al., 2000) and nPM (cuomo et al., 2008; Sarek et al., 2010).
V-cyclin-cdK6 is regulating cell cycle progression by phosphorylating and inactivating 
the cell-cycle checkpoint protein Rb (chang et al., 1996; Godden-Kent et al., 1997). In 
addition, v-cyclin-cdK6 overcomes cell cycle arrest by phosphorylating and degrading 
cyclin-dependent kinase inhibitors (cKI) such as p27KIP1, p21cIP1 and p16InK4 
(Jarviluoma et al., 2006; Sarek et al., 2006; Swanton et al., 1997). Similar to many other 
oncogenes, v-cyclin can also lead to p53-dependent apoptosis in the presence of high 
levels of cdK6 (ojala et al., 1999; ojala et al., 2000), or stress signals (Verschuren 
et al., 2002). To promote apoptosis, v-cyclin-cdK6 phosphorylates and inactivates the 
cellular	anti-apoptotic	protein	Bcl-2	(Ojala	et	al.,	2000).	Centrosome	amplification	and	
aneuploidy are frequently observed in v-cyclin expressing cells (Koopal et al., 2007; 
Verschuren et al., 2002). Additionally, v-cyclin causes a dnA damage response and 
senescence in endothelial cells (Koopal et al., 2007). In animal model studies, transgenic 
mice expressing v-cyclin in Lecs under control of the VeGFR-3 promoter suffered 
from	pleural	fluid	accumulation	due	 to	dysfunction	of	 lymphatic	fluid	absorption	and	
lived	 no	more	 than	 6	months	 (Sugaya	 et	 al.,	 2005).	Another	 Eμ-v-cyclin	 transgenic	
mouse model (targeted expression of v-cyclin to the B and T lymphocyte compartment 
via	 the	Eμ-promoter/enhancer)	 developed	T	 and	B	 cell	 lymphomas	 in	 the	 thymus	 or	
spleen, with accelerated lymphoma formation in p53-/- background (Verschuren et al., 
2004; Verschuren et al., 2002).
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3.3.4. vgpCR
KSHV immediate-early lytic protein Viral G-protein-coupled receptor (vGPcR) is a 
constitutively active homologue of the human angiogenic IL-8 receptors cXcR1 and 
cXcR2 (Ahuja and Murphy, 1993; Arvanitakis et al., 1997; cesarman et al., 1996; Guo 
et al., 1997), which increases endothelial cell survival and proliferation by activating 
MAPK, PI3K, nF-kB and p38 MAP pathways (Schwarz and Murphy, 2001; Smit et 
al., 2002; Sodhi et al., 2000). vGPcR was shown to have potent oncogenic capabilities 
in vitro, as evidenced by directly transforming murine nIH3T3 cells and immortalizing 
human umbilical vein endothelial cells (HUVec) with autocrine activation of VeGFR2 
and downstream Akt signaling pathway (Bais et al., 1998; Bais et al., 2003; couty et 
al., 2001; Jensen et al., 2005; Montaner et al., 2001). Moreover, as a homolog of the 
chemokine receptor, vGPcR also directly enhances expression of a variety of other 
cytokines and growth factors including IL-4 and GM-cSF (Pati et al., 2003), IL-6 and 
TNF-α	(Schwarz and Murphy, 2001),	Gro-α	(Montaner et al., 2004), and ccL-2 (choi 
and nicholas), which are rich in tumor microenvironment and facilitate tumor cell 
proliferation,	angiogenesis,	and	inflammation.	In	addition,	vGPCR	is	capable	of	Notch	
signaling pathway activation by modulating the expression of notch ligand dLL4 in 
Lecs (emuss et al., 2009). 
vGPcR transgenic mice developed KS-like multicentric, angioproliferative lesions with 
surface	markers	and	cytokine	profiles	resembling	those	of	KS,	suggesting	 that	a	self-
perpetuating autocrine/paracrine loop induced by vGPcR might contribute to KS and 
other KSHV-driven malignancies (Guo et al., 1997; Yang et al., 2000). This scenario 
could explain why only a small group of tumor cells express vGPcR in vGPcR-
driven KS-like tumors in mice. Likewise, this obvious potential to affect the tumor 
microenvironment is a good clue to understand that only a relatively minor subset of 
cells in tumor regions are KSHV infected and even fewer express lytic genes such as 
vGPcR (dupin et al., 1999; Linderoth et al., 1999; Staskus et al., 1997; Teruya-Feldstein 
et al., 1998).  Importantly, the mouse bone marrow endothelial-lineage cells haboring 
a	 KSHV	 Bacterial	 Artificial	 Chromosome	 (BAC)	 form	 KS-like,	 angioproliferative	
tumors in mice. In these vascularized sarcoma lesions, the spindle cells express the 
KSHV hallmark protein LAnA and the Lec marker /podoplanin, overexpress VeGF 
and Angiopoietin ligands and receptors, and display KSHV and host transcriptomes 
reminiscent of KS. However, the inhibition of vGPcR in tumors inhibited angiogenicity 
and tumorigenicity, supporting the important role of vGPcR in KSHV-dependent KS 
(Mutlu et al., 2007). 
In addition, a few other KSHV proteins including vIL-6, K1, vIRF1, K15 and Kaposin 
A/B have shown transforming potential in different assays. Most likely the co-operation 
between different KSHV-encoded genes is required for tumorigenesis (Mesri et al., 
2010). A summary of KSHV viral proteins involved in KSHV pathogenesis is shown in 
Figure 4.
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Figure 4. latent and lytic viral proteins involved in KSHV pathogenesis. In infected cells, 
expression of KSHV latent proteins (such as LAnA, vFLIP, v-cyclin and vIRF3; shown in 
green) and lytic proteins (such as vGPcR, K1, vIL-6, K15 and vIRF1; shown in red) pirate host 
signaling pathways, leading to the expression and secretion of a variety of cellular factors through 
autocrine or paracrine mechanisms. These provide infected cells a survival advantage, together 
with	 enhanced	 angiogenesis,	 inflammation	 and	 invasive	 potentials	 in	 the	 context	 of	 KSHV-
induced	 tumors.	 CDK,	 cyclin-dependent	 kinase;	 GSK3β,	 glycogen	 synthase	 kinase	 3β;	 HIF,	
hypoxia-inducible	factor;	IAPs,	inhibitor	of	apoptosis	proteins;	NF-κB,	nuclear	factor-κB;	PKC,	
protein	kinase	C;	ROS,	reactive	oxygen	species	(Adapted	and	modified	from	Mesri,	Cesarman	
and Boshoff, 2010).
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aiMS OF THE STudY
The switch from latency to productive viral replication (reactivation) is essential in the 
KSHV viral life cycle, and recent clinico-epidemiological studies support the importance 
of	lytic	replication	in	the	development	and	progression	of	KS.	The	first	aim	of	the	thesis	
was to identify novel cellular kinases that are involved in KSHV reactivation from 
latency and the production of progeny virus particles. 
As infection of primary Lecs by KSHV does not readily lead to transformation of 
the cells, the second aim of this work was focused on gaining a deep understanding of 
cellular events involved in the KSHV-induced ec transformation by using a 3d cell 
model better mimicking the in vivo tumor microenvironment.
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MaTERialS aNd METHOdS
The materials and methods of this study are listed below, for most of them detailed 
descriptions can be found in the original publications here referred to by Roman numerals.
Table 1. Cell lines used in this study
Cell line description Source or  reference
used  
in
U2oS Human osteosarcoma cell line; KSHV-/eBV- ATcc I,II, III
Bc-3 Human primary effusion lymphoma cell line (PeL); KSHV+/eBV-
dr. ethel 
cesarman 
(Arvanitakis et 
al., 1996)
II
BcBL-1
Human primary effusion lymphoma cell line 
heterozygous for the M246I mutation in one of the 
copies of the TP53 gene (PeL); KSHV+/eBV-
A. Moses; nIH 
AIdS Research 
(cat# 3233 from 
McGrath and 
Ganem)
II, III
BJAB B-lymphoblastoid cell line dr. J. Salonen II
dG-75 Burkitt lymphoma cell line; KSHV-/eBV- ATcc II
eA.hy926
endothelial cell line derived from fusing human 
umbilical vein endothelial cells with the human lung 
carcinoma cell line A594; KSHV-/eBV-; wt p53
dr. Kari Alitalo
(edgell et al., 
1983)
II
Vero I, II,III
Lec Primary juvenile foreskin lymphatic endothelial cells Promocell III
HeK-293 Human embryonic Kidney 293 cells ATcc I,II,III
rKSHV-
Vero 
Vero cells latently infected with a recombinant GFP-
expressing KSHV (rKSHV.219)
(Miller et al., 
2007) I,II,III
Bec Primary juvenile foreskin blood endothelial cells Promocell III
293-FT Human embryonic Kidney 293 cells with T antigen Invitrogen III
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Table 2. Expression vectors used in this study
Vector description Source orreference
used
in
lentiviral vectors
psin psin-McS backbone
dr. chris Boshoff 
(emuss et al., 
2009)
III
pSin-vFLIP Targets vFLIP
dr. chris Boshoff 
(emuss et al., 
2009)
III
pSin-vGPcR Targets vGPcR 
dr. chris Boshoff 
(emuss et al., 
2009)
III
pLenti6/V5-deST-GFP encodes GFP dr. Juergen Haas III
pLenti6/V5-deST-
LAnA encodes LAnA dr. Juergen Haas III
Retroviral vectors
pMX dr. Kari Alitalo III
pMX-MT1-MMP Targets MT1-MMP dr. Kaisa Lehti III
pBMn encodes GFP dr. emmy Verschuren III
v-cyclin-pBMn 
(KpBMn) encodes v-cyclin
dr. emmy 
Verschuren III
Mammalian expression vectors
pcdnA.3-LAnA encodes full length of LAnA (Viejo-Borbolla et al., 2003) II
pcdnA.3-LAnA 
SS205/206RR
encodes full length of LAnA with serine to arginine 
(SS205/206RR) mutations
(Viejo-Borbolla 
et al., 2003) II
pcMV6- Pim2 encodes full length of human Pim2 I
pcdnA3.1/V5-Hisc 
-Pim1 encodes full length of human Pim1 I, II
pcdnA3.1/V5-Hisc 
-Pim1Kd
encodes full length of human Pim1 with K67M 
mutation I, II
PcdnA3.1-V5-LacZ-
Pim2 encodes full length of human Pim2 I, II
pcdnA3.1/V5-Hisc 
-Pim2Kd
encodes full length of human Pim2 with K61M 
mutation I, II
pcdnA3.1/V5-Hisc 
-Pim3
encodes full length of human Pim3 I, II
pcdnA3.1/V5-Hisc 
-Pim3Kd
encodes full length of human Pim3 with K69M 
mutation I, II
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Vector description Source orreference
used
in
pcdnA3.1/V5-Hisc empty vector with V5 and His tagging and LacZ selection I, II
pGL2-oRF50p
pGL2-oRF50p backbone containing the RTA 
promoter (3 kb sequence upstream of the RTA 
translation initiation codon) 
(deng et al., 
2000) II
pGL3-7xTR the luciferase reporter containing seven terminal repeats (TR) of KSHV genome, pGL3-7xTR
(Garber et al., 
2001) II
pRL-cMV-luc the luciferase reporter control that constitutively expresses Renilla luciferase II
E.coli expression vectors
pGeX-6P-1-GST-
Pim-1
The GST-tagged Pim-1 generated by PcR subcloning 
into the pGeX-6P-1 vector II
pGeX-6P-1-GST-
Pim-1Kd
The GST-tagged Pim-1Kd constructs generated by 
PcR subcloning into the pGeX-6P-1 vector II
pGeX-2T-GST pGeX-2T plasmid used to produce GST in control samples Ge Healthcare II
pGeX4T1-GST-c-
LAnA
The GST-tagged carboxy-terminal LAnA (GST-c-
LAnA; amino acids 972-1162) 
(Viejo-Borbolla 
et al., 2003) II
pGeX4T1-GST-n-
LAnA
The GST-tagged amino-terminal LAnA (GST-n-
LAnA; amino acids 1-340)
(Viejo-Borbolla 
et al., 2003) II
pGeX4T1-GST-
n6LAnA 
The GST-tagged truncated amino-terminal LAnA 
(GST-n6-LAnA; amino acids 100-340) II
pGeX4T1-GST-
n11AnA
The GST-tagged truncated amino-terminal LAnA 
(GST-n11-LAnA; amino acids 24-100) II
pGeX4T1-GST-n17-
LAnA
The GST-tagged truncated amino-terminal LAnA 
(GST-n17-LAnA; amino acids 75-200) II
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Table 3. primary antibodies used in this study
antibody description Source orreference
used
in
a-SMA (1A4) cy-3 conjugated mouse monoclonal antibody against human a-smooth muscle actin (a-SMA) Sigma III
fibronectin Mouse	antibody	against	human	fibronectin dr. Antti Vaheri III
K8.1 A/B Mouse monoclonal antibody against K8.1 ABI Biotechnologies I, II
LAnA Rabbit polyclonal antibody against LAnA (Sharma-Walia et al.) III
LAnA (HHV8-
oRF73) Rat monoclonal antibody against LAnA 
ABI 
Biotechnologies I, II,III
LYVe-1 Rabbit polyclonal antibody against LYVe-1 dr. Pirjo Laakkonen III
MT1-MMP Mouse monoclonal antibody against MT1-MMP chemicon III
n-cadherin Rabbit polyclonal antibody against n-cadherin Bd Biosciences III
oRF59 Mouse monoclonal antibody against oRF59 (chan et al., 1998) I, II, III
PdGFR-a Mouse monoclonal antibody against PdGFR-a Santa cruz III
PdGFR-b Mouse monoclonal antibody against PdGFR-b Santa cruz III
PecAM-1 Mouse monoclonal antibody against human PecAM-1 dako III
Pim-1 (12H8) Mouse monoclonal antibody against Pim-1 Santa cruz I, II
Pim-2 Mouse monoclonal antibody against Pim-2 Atlas I, II
Pim-3 (c-term) Rabbit polyclonal antibody against Pim-3 Abgent II
pTyK(4G10) Mouse monoclonal anti-phosphotyrosine antibody Millipore III
podoplanin affinity-purified	rabbit	polyclonal	antibody	against	human podoplanin
(Breiteneder-
Geleff et al., 1999) III
transgelin Mouse monoclonal antibody against transgelin Abcam III
Tubulin (5H1) Mouse monoclonal antibody against tubulin Bd Biosciences-Pharmingen I, II,III
Ve-cadherin Mouse	antibody	against	human	fibronectin Bd Biosciences III
VeGFR3 (9d9) Rat monoclonal antibody against VeGFR3 dr. Kari Alitalo III
vimentin (V9) Mouse monoclonal antibody against human vimentin dako III
V5 Mouse monoclonal antibody against V5 tag peptide Invitrogen I, II
anti-Zo-1 Rabbit polyclonal antibody against  Zo-1 Zymed III
Mouse IgG (sc-2025) Mouse antibody isotype Santa cruz III
Rabbit IgG (sc-2027) Rabbit antibody isotype Santa cruz III
Rat IgG  (sc-2026) Rat antibody isotype Santa cruz III
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Table 4. Chemicals used in this study
chemical Working concentration Source orreference
used
in
SU16f 100nM Tocris Bioscience III
GM6001 10µM calbiochem III
TIMP1 50nM R&d Systems III
TIMP2 50nM R&d Systems III
dAPT 5 µM Sigma III
SB431542 10µM Sigma III
TGF-b blocking 
antibody 15µg/ml R&d Systems III
nocodazole 100ng/ml Sigma III
cytochalasin d 1µM Sigma III
dll4-Fc
10µg/ml; Signal peptide and extracellular domain 
of recombinant human dLL4 (delta-like protein 4; 
delta4) (aa 1-529) are fused at the c-terminus to the 
Fc portion of human IgG)
(Zheng et al., 
2011) III
recombinant TGF-b1 1ng/ml R&d Systems III
PdGF-AA 25ng/ml R&d Systems III
PdGF-BB 25ng/ml R&d Systems III
PMA 20ng/mL12-o-tetradecanoyl phorbol-13-acetate (or called TPA) Sigma II, III
ionomycin 500ng/ml Sigma II, III
naB 1.35mM Sigma I, II
thrombin 2 U/ml Sigma III
aprotinin 400mg/ml Sigma III
VeGF-A 50ng/ml R&d Systems III
VeGF-c 50ng/ml R&d Systems III
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Table 5. Methods used in this study
Methods used  in
chromatin Immunoprecipitation (chIP-on-chIP) III
cytocentrifugation I, II, III
dnA extraction I, II, III
Gene knockdown by RnA interference II, III
Generation spheroids in 3 dimentional (3d) matrix III
High content microscopy imaging I, II
Immunofluorescence	microscopy I, II, III
Immunohistochemistry III
Immunoprecipitation I, II
Invasion assay III
In vitro kinase assay I, II
Lenti- and retroviral production III
Luciferase reporter assay II
Mammalian cell culture I, II, III
Microarray Processing III
Protein	purification II
Production of wt and recombinant KSHV virions I, II,III
Quantitative image analysis II, III
Quantitative real-time PcR II, III
Recombinant protein production in bacteria II
RnA extraction and Reverse transcription II, III
SdS-PAGe and immunoblotting I, II, III
Statistical methods I, II, III
Transduction of mammalian cells I, II, III
Transfection of cells I, II, III
Ultracentrifugation I, II, III
Virus infection of mammalian cells I, II, III
Virus titer determination I, II, III
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Cell culture
PeL cell lines as well as KSHV-negative BJAB cell line were cultured in RPMI 1640 
medium supplemented with 10% fetal calf serum (FcS) (Invitrogen), 100 U/ml penicillin 
G,	and	100	μg/ml	streptomycin.	HEK-293,	Vero,	U2OS	human	osteosarcoma,	EA.hy926	
endothelial	cells	and	WI-38	cells	 (ATCC)	were	grown	 in	Dulbecco’s	Modified	Eagle	
Medium	(DMEM)	supplemented	with	10%	FCS,	100	U/ml	penicillin	G,	and	100	μg/
ml streptomycin. Primary juvenile foreskin Lec and Bec cells were cultured in the 
basal ec medium plus supplement pack (Promocell), in the presence of 5% human 
serum, 25µg/mL amphotericin B, and 25µg/mL gentamycin. All cells were cultured in a 
humidified	5%	CO2 atmosphere at 37°c.
Virus reactivation assay 
Viral reactivation was addressed in Vero and eA.hy926 cells stably infected with 
recombinant KSHV (rKSHV.219) (Vieira and o’Hearn, 2004). The rKSHV.219 is 
a	 double-reporter	 virus,	which	 expresses	 the	 green	 fluorescent	 protein	 (GFP)	 from	 a	
constitutively	active	EF-1-promoter,	and	can	be	induced	to	express	the	red	fluorescent	
protein (RFP) from the RTA-responsive KSHV lytic promoter for polyadenylated nuclear 
RnA (PAn). To address the effect of Pim kinases or their mutants on reactivation, 
rKSHV.219-Vero and -eA.hy926 cells were seeded on 6- or 24-well dishes and transiently 
transfected with the empty vector pcdnA3.1 or vectors expressing wt or kinase-dead 
Pim family members. In brief, 2x105 rKSHV.219-Vero and -eA.hy926 cells per well 
were plated on a 6-well plate. on the following day, 1µg aliquots of dnA samples 
were mixed with serum-free medium containing 3µl FuGene Hd (Roche, nutley, nJ) 
according to the manufacturer’s protocol. one day after transfection, the medium was 
changed	into	fresh	DMEM	medium.	To	monitor	transfection	efficiency,	pcDNA/DsRed	
plasmid was transfected into duplicate wells and the number of dsRed-positive cells 
was	determined	by	fluorescence	microscopy.	The	typical	efficiency	of	transfection	was	
between 15-20%. After 48 h, cells were treated for 2 h with a low-titer baculovirus 
(BacK50) expressing the KSHV lytic activator oRF 50/RTA. This triggered basal 
reactivation but led to a low level of RFP induction (2.5% in rKSHV-Vero, and 1.9% 
in rKSHV- eA.hy926) over the non-treated control (0.4% in rKSHV-Vero, and 0.05% 
in rKSHV-eA.hy926). cells transfected with the control vector and treated as above 
served as negative controls, while positive controls were prepared by treating these cells 
for 2 h with a high-titer BacK50, followed by replacement with media containing 1.25 
mM naB (Sigma) to induce maximal reactivation (25% in rKSHV.219-Vero and 13% in 
rKSHV.219-EA.hy926	cells).	30	h	after	baculovirus	infection,	cells	were	fixed	with	4%	
paraformaldehyde (PFA) and RFP expression was monitored using an automated high-
content	fluorescence	microscope	Arrayscan	4.5	(Cellomics).	To	measure	completion	of	
the lytic cascade and production of progeny virions, naïve target cells (U2oS) were 
infected 72 h later with 500 µl of the supernatant from transfected/reactivated cells in the 
presence of 8 ug/ml polybrene to enhance the infectivity. Plates were spin-transduced by 
centrifugation at 1,050 g for 30 minutes at room temperature and returned to 37°c, 5 % 
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co2 for 2 h, after which the supernatant was replaced with complete medium. At 72 h 
after	infection,	target	U2OS	cells	were	fixed	by	4%	PFA	and	GFP	intensity	was	analyzed	
by cellomics Arrayscan 4.5. 
Purification	of	the	Glutathione-S-transferase	(GST)-fusion	proteins
GST-fusion proteins were produced in e. coli BL21 (GST-Pim-1 and -Pim-1Kd) or 
dH5a	cells	(the	GST-LANA	proteins).	Briefly,	bacteria	were	grown	at	30ºC	for	the	GST-
Pim-1, -Pim-1Kd, and for all the GST-n-LAnA forms (full length and truncations), or 
at	25ºC	for	the	GST-C-LANA.	The	proteins	were	induced	with	200	nM	IPTG	for	the	
GST-Pim-1, -Pim-1Kd, 100 µM for all the GST-n-LAnA forms for 6 h, or with 100 µM 
for the GST-c-LAnA for 16 h before the cells were harvested. The bacteria were lysed 
in PBS containing 0.5 % Triton X-100 and protease inhibitors (complete Mini edTA- 
free, Roche) and sonicated. Solubilized GST-fusion proteins were bound to glutathione 
sepharose beads (Ge Healthcare) and eluted with buffer containing 30 mM glutathione 
in 75 mM Tris, pH 8.0. To cleave off the GST-tag from the Pim-kinases, PreScission 
protease was used according to the manufacturer´s instructions (Ge Heatlhcare).
immunoprecipitation and kinase assay
To induce KSHV lytic replication, Bc-3, BcBL-1 and control BJAB cells were treated 
with either 20 ng/ml TPA or 2 mM naB for 48 h prior to lysis into the eLB lysis buffer 
(150 mM nacl; 50 mM HePeS, pH 7.4; 0.1% Igepal; 5 mM edTA; 2 mM dTT; 1 mM 
phenylmethylsulfonyl	fluoride	[PMSF];	2	µg/ml	leupeptin;	2	µg/ml	pepstatin;	and	1.5	
µg/ml aprotinin). 600 µg of the whole-cell extracts were incubated with anti-Pim-1 or -3 
antibodies for 2 h at +4°c. Immunocomplexes were coupled to protein-A or G Sepharose 
beads for an additional 1.5 hour at 4°c and washed 3 times with the lysis buffer followed 
by one wash with the kinase buffer (20 mM Tris-Hcl, pH 7.5; 50 mM Kcl; 7.5 mM 
Mgcl2; 1 mM dTT; 25 mM ß-glycerophosphate;
 leupeptin 2 µg/ml; pepstatin 2 µg/ml; 
and aprotinin 1.5 µg/ml). complexes bound to protein-A/G beads were either directly 
subjected to a kinase reaction towards co-precipitated proteins or were supplemented 
with exogenous GST-fusion proteins as substrates. For in vitro kinase assays, wild-type 
and	kinase-dead	Pim-1	proteins	produced	in	bacteria	as	GST-fusion	proteins	were	purified	
and cleaved by Precission protease (Ge Healthcare). Kinase reactions were performed in 
the	presence	of	2	µCi	(0.074	MBq)	of	[32P]	adenosine triphosphate (ATP) for 30 minutes 
at 30°c and stopped by boiling in Laemmli buffer for 10 min. Phosphorylated proteins 
were resolved in 8% SdS-PAGe, transferred onto nitrocellulose membranes (Schleicher 
and Schuell, dassel, Germany) and analysed by autoradiography and Western blotting 
when	needed.	Equal	 loading	of	proteins	was	 confirmed	with	Colloidal	Coomassie	or	
Ponceau staining.
luciferase reporter assays
The luciferase reporter plasmids were transfected with FuGene Hd (Roche, nutley, 
nJ) into HeK-293 cells according to the manufacturer’s protocol. All transfections were 
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performed with equal amounts of dnA by normalization with empty vector. The pRL-
cMV plasmid that constitutively expresses Renilla luciferase was included as an internal 
control.	Relative	luciferase	activities	were	calculated	by	dividing	the	normalized	firefly	
luciferase activity of each reporter by that of pGL3 or pGL2 plasmid in transfected cells. 
24 h or 48 h after the transfection, cells were harvested, washed in PBS and lysed into 
the cell lysis buffer provided by the manufacturer of the dual-Luciferase Reporter Assay 
System kit (Promega). 100 µl of the cell lysate was used for the reporter assay using a 
dcR-1 luminometer (dIGene, Gaithersburg, Md). An aliquot of the cell lysate was 
used for Western blotting to ensure equal expression of the transfected cdnAs.
Short-term replication assay
4x105 293 cells were plated per one well of a 6 well plate. on the next day cells 
were transfected with pGTR4 or pGTR4:73 plasmids (Grundhoff and Ganem, 2003), 
both of which contain four KSHV terminal repeats (TR) and GFP coding sequence. 
pGTR4:73 additionally encodes the KSHV LAnA protein. Where indicated cells were 
also transfected with plasmids expressing Pim proteins or their respective kinase dead 
mutants. In addition each sample contains as well the peGFP-c1 (clonetech) plasmid, 
which is used as an internal control, since it does not replicate, but can be detected with 
the same probe as the pGTR4/pGTR4:73 plasmids. At 24h post transfection, cells were 
split in half to stimulate replication. 48h later the cells were harvested in 300µl lysis 
buffer (10 mM Tris-Hcl, 10 mM edTA, 0.6% SdS) per sample. The chromosomal dnA 
was precipitated overnight with 0.85 M nacl. Subsequently, an aliquot was removed 
for the analysis of protein expression by Western blotting and the episomal dnA was 
purified	using	phenol-chlorophorm	extraction.	DNA	was	precipitated	with	ethanol	and	
dissolved in 20µl of water. 90% of dnA was digested for al least 48h with 40U of MfeI 
(neB) and 40U dpnI (neB) and the remaining 10% with 10U MfeI only. The MfeI/dpnI 
digestion	reveals	the	efficiency	of	replication,	while	the	single	MfeI	digestion	is	used	to	
estimate the amount of input dnA. Subsequently half of each digest was loaded on a 
0.8% agarasoe gel, separated and transferred to a nitrocellulose membrane by Southern 
blotting. A sequence coding for GFP, labelled with alkaline phosphatase was used as a 
probe to detect the bands of interest (Ge Healthcare/Amersham Biosciences).
KSHV production, titer determination and infection of lECs
GFP-expressing rKSHV.219 was produced as described above. Wild type (wt) KSHV 
was produced from BcBL-1 cells induced with 20ng/mL PMA. The supernatant was 
collected after three days by ultracentrifugation (SW28.1, 21,000 rpm at 4oc for 2 h), and 
resuspended in Tne buffer (150mM nacl, 10mM Tris pH 8, 2mM edTA, pH 8). The 
virus titers were determined by infecting naïve U2oS cells with serial dilutions of the 
concentrated	virus	preparation	and	infected	cells	were	identified	by	staining	for	LANA	
at 48 h post infection. Typically we obtained virus titers of 1x106 infectious viral particles 
per ml. For infection, the Lecs were split at a density of 2.5x105 cells per a 6-well, and 
spin-infected with a multiplicity of infection (MoI) of ~3 in serum free medium with 
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8µg/ml	polybrene.	The	efficiency	of	infection	in	the	K-LEC	cultures	with	wt	KSHV	was	
between 20-40% by LAnA staining or 30-50% with recombinant rKSHV.219 by GFP 
expression in the K-Lecs. To address the requirement of infectious virus, virus was 
inactivated by UV light (UV-KSHV). To this end, an aliquot of freshly produced KSHV 
was treated by 3000 mJ of UV-c light using UV Stratalinker 1800 (Stratagene) as a light 
source,	and	the	loss	of	infectivity	was	confirmed	by	measuring	the	virus	titer.
generation of lEC spheroids
Confluent	monolayers	of	 spindling	K-LECs	or	uninfected	 control	LECs	were	 seeded	
into 0.5% agarose pre-coated, nonadherent round-bottom 96-well plates at 4000 cells 
per well. After 16 h to 24 h incubation at 37°c, the formed spheroids were harvested 
and	embedded	into	the	fibrin	gel	consisting	of	plasminogen-free	human	fibrinogen	(final	
concentration	3mg/ml;	Calbiochem)	and	human	thrombin	(final	concentration	2	U/ml;	
Sigma) in 50 ml Hank’s Balanced Salt Solution supplemented with 400mg/ml aprotinin 
(Sigma). The gels were cast onto the bottom of 24-well plates and incubated for 1 h at 
37°c to allow complete gelling followed by addition of ec culture medium.
Quantification	of	spheroid	sprouting
To quantify the sprouting of the spheroids the number of sprouts per spheroid was 
determined	from	phase	contrast	images	acquired	with	Zeiss	Axiovert	200	epifluorescence	
microscope	(five	to	 ten	spheroids	were	quantified	per	condition).	The	sprouts	and	the	
spheroid body boundaries were depicted on the images using the Inkscape software 
[http://www.inkscape.org].	The	 vector	 graphic	 data	was	first	 rendered	with	 Inkscape,	
and then analyzed in a pipeline created in the Anduril framework (ovaska et al., 2010). 
This pipeline searches the sprout lines and counts them, gives the total length of the 
sprouts	and	the	spheroid	body	area.	Sprouting	is	defined	as	the	total	length	of	the	sprouts	
normalized to the spheroid body area.
invasion assay
collagen invasion was assessed essentially as previously described (Hotary et al., 
2000). collagen gels were cast into the upper chamber of Falcon cell culture inserts 
(Bd Biosciences) with 8 mm pore membranes in 24-well cell culture plates and allowed 
to form a gel at +37°c for 1 h. Lecs (2x105 cells/insert) were added on top of the 
gel, and ec medium supplemented with recombinant human HGF (25ng/ml, R&d 
systems) was added to the lower chamber. The cells were cultured at 37°c for 7-14 days 
replenished	with	complete	media	every	second/third	day.	The	gels	were	then	fixed	in	3%	
PFA,	dehydrated	and	embedded	into	paraffin.	Invading	cells	were	quantified	from	H&E	
stained	paraffin	sections	using	a	Leica	DM	LB	microscope.
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Microarray processing
RnA from biological triplicates of K-Lec spheroids and Lec control spheroids was 
collected on day three using the Rneasy Mini kit (Qiagen). RnA integrity and quantity 
was assessed using RnA 6000 nano chips (Agilent 2100 bioanalyzer). Affymetrix Hg-
U133 plus 2.0 oligonucleotide arrays containing more than 45,000 human gene probes 
were used for the hybridizations according to standard procedures (Affymetrix), and 
analyzed essentially as previously described (Wang et al., 2004a). Genome annotations 
of the array data were taken from the Bioconductor repository package ‘hgu133plus2.db’ 
(Bioconductor 2.6 cdF and probe annotations. http://www.bioconductor.org/packages/
release/data/annotation/). enrichment of gene sets within the K-Lec spheroids over the 
control Lec spheroids data was determined using gene set enrichment analysis (GSeA) 
software from the Broad Institute.
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RESulTS aNd diSCuSSiON
1.	 Identification	of	Pim-1	as	a	novel	kinase	regulating	KSHV	viral	
reactivation (i)
1.1. a large-scale human cdNa kinome screen
The association of KSHV with a human neoplasm and the large number of cellular 
counterparts in the KSHV genome make it of tremendous interest to determine the role of 
virus-host interactions in KSHV pathogenesis. The switch from latency to lytic replication 
is an elementary decision in the viral life cycle and holds substantial importance for the 
herpesviral tumorigenesis (Grundhoff and Ganem, 2004; Song et al., 2004). Multiple host 
signal-transduction pathways have been suggested to mediate the switch between KSHV 
latency and productive infection, but they have not been rigorously addressed. Therefore 
we set to investigate which cellular kinases would be involved in the reactivation of the 
KSHV lytic replication cycle and the production of virus particles (I).
To allow an unbiased genome-wide analysis of the cross-talk between cellular kinase 
pathways and KSHV reactivation, I developed and optimized a gain-of-function screen 
utilizing a novel expression library for 488 human protein kinase cdnAs (Fig. 1 in 
I). In the screen setup, a monkey kidney cell line, Vero cells stably infected with a 
recombinant KSHV (rKSHV.219 (Vieira and o’Hearn, 2004)) were used, which express 
the	green	fluorescent	protein	(GFP)	from	the	constitutively	active	EF-1-promoter	and	
can	be	induced	to	express	the	red	fluorescent	protein	(RFP)	from	the	KSHV	early	lytic	
promoter for polyadenylated nuclear RnA (PAn), which is the most abundant transcript 
made during the lytic phase (Vieira and o’Hearn, 2004).
In the screen, individual cdnAs of the genome-wide protein-kinase collection were 
transfected into rKSHV.219-Vero cells. At 48 hours post transfection of the kinases, cells 
were infected with a low-titer recombinant baculovirus encoding RTA (BacK50), the 
KSHV replication and transcription activator, for 2 hours to induce basal reactivation. 
Priming with exogenous RTA is needed as the latency program in the infected Vero 
cells is very tight, and a basal expression of RTA can enhance the activation of viral 
lytic cascade by cellular protein kinases. Induction of RFP expression was monitored by 
an automated high-content microscope (cellomics ArrayScan HcS instrumentation) 30 
hours after the baculovirus infection. For positive controls, maximal viral reactivation 
was achieved by treatment with high-titer RTA-encoding baculovirus and naB, a potent 
reactivation enhancer due to its histone deacetylase inhibitor function.
Analysis	of	 the	RFP	quantitation	data	allowed	 identification	of	66	cDNA	hits,	which	
increased viral reactivation more than 4-fold above the basal level. In statistics, the 
Z-factor and Screening Window are proposed to be key measures of the quality or power 
of a high-throughput screening (HTS) assay. The Z-factor and Screening Window are 
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defined	in	terms	of	four	parameters:	the	sample	means	and	sample	standard	deviations	of	
both	the	positive	(p)	and	negative	(n)	controls	(μp,	σp,	and	μn,	σn).	Given	these	values,	the	
Z-factor	and	Screening	Window	are	defined	as:	Z	factor=1-3(σp+σn)/|μp-μn|;	Screening	
Window=(|μp-μn|-3(σp+σn))/σn.	The	Z-Factor	between	0.3-1	and	the	screening	window	
>2 suggest the response in a particular assay is large enough to warrant further attention 
(Zhang et al., 1999). In the primary KSHV cdnA kinome screening assay, the calculated 
Z-factor	 and	 Screening	Window	were	 0.534	 and	 4.595,	 respectively,	 confirming	 the	
assay to be robust and reproducible.
1.2. Exogenous expression of the pim-1 kinase induces KSHV reactivation 
The hits (kinase cdnAs) of the primary HcS-screen were thereafter individually 
transfected to rKSHV.219-Vero cells for a secondary screen assay perfomed in 24-well 
plates, followed by priming of the lytic cycle with RTA-expressing baculovirus infection, 
and the phenotypes were characterized further by high-content microscopy as above.
In the secondary rescreen, a new step was added to the assay to address if the kinases 
identified	in	the	first	screen	were	able	to	 induce	the	full	 lytic	cascade	resulting	in	 the	
production of progeny virions. To this end, duplicates of the transfections were prepared, 
and	one	of	 them	was	fixed	and	analyzed	 for	 the	RFP	expression	already	at	 about	30	
hours post lytic induction as an indication of activity of the lytic PAn promoter, the 
assay used in the primary screen. The second well of the duplicates was analysed at 
48 hours after the transfection. Then the supernatants were harvested, centrifuged, and 
filtered	to	exclude	the	transfer	of	GFP-expressing	cells	from	the	transfection	plate	and	
finally	replica-plated	on	human	osteosarcoma	(U2OS)	cells.	U2OS	cells	were	chosen	as	
target cells due to their good susceptibility to KSHV infection, and suitable morphology 
for	automated	microcopy	(our	unpublished	results).	The	target	cells	were	quantified	for	
GFP expression after 48 hours as an indication of infectious virions in the supernatant. 
This approach allowed differentiation of cdnAs inducing lytic reactivation at the early 
transcriptional level from those affecting later stages of viral life cycle (e.g. assembly, 
egress). 10 out of 66 hits from the primary screen were validated in the rescreen, and 
processed to an even larger format rescreen (6-well format). These screening steps led to 
identification	of	Pim-1	kinase	as	a	novel	kinase	involved	in	KSHV	reactivation	(Fig.	3A	
in	I).	The	outline	of	the	high-content	screening	(HCS)	workflow	is	depicted	in	Figure	5.	
In this large-scale human kinome screen, we chose to use the gain-of-function strategy. 
Although RnAi technology allows for large-scale loss-of-function assays to be 
performed, the limitations of this technology need to be acknowledged and mitigated. 
This owes to the potential for RnAi screen to result in ‘‘off-target effects,’’ or the 
silencing	 of	 untargeted	mRNAs,	 along	 with	 variability	 both	 in	 siRNA	 efficacy	 and	
protein half-lives that will ultimately result in different silencing levels of proteins. 
Therefore the gain-of-function approach can be used as a complementary tool to 
identify genes that are not expressed in the cell type tested, act redundantly, or activate 
the pathways analyzed under pathological conditions. In addition, the best models for 
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different cellular signaling events especially in the context of viral infections may not 
be derived from cells of human origin. In this KSHV reactivation screen, the monkey 
Vero cell line was used as the screen cell model, which would limit the utility of human 
siRnA libraries. However, such restriction does not limit the use of human cdnA tools 
in cells from other mammalian species.
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Figure	 5.	Workflow	 of	 the	 human	kinome	 screen	 for	KSHV	 reactivation.	 Individual 466 
kinases from the oRF kinome library were transfected in rKSHV.219-Vero cells for 48 hours. The 
transfected cells were treated with the RTA encoding baculovirus to induce basal reactivation, and 
the RFP expression was monitored by cellomics ArrayScan HcS instrumentation 30 hours later. 
The hits obtained from data analysis were used for the secondary rescreen in large format data. 
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1.3. Validation of pim-1 as a kinase inducing KSHV reactivation
Ectopic	expression	of	protein	kinases	may	induce	artificial	effects	due	to	scaffolding	or	
other nonenzymatic functions of kinases. To exclude this possibility, we took advantage 
of our human kinome cdnA library in which a corresponding set of catalytically inactive 
kinases has been produced based on structurally similar kinase domains and critical 
catalytic residues shared by all kinases. These inactive kinase mutants lead to loss-of-
function effects of corresponding kinases and can be used to test whether the kinase 
activity is required for the observed phenotypes. To further validate the screen, the above 
reactivation assay was repeated with mutant cdnAs of the Pim-1, the ATP binding site 
of which was disrupted by a single point mutation (K67M) (Fig. 3 in I). This Pim-1Kd 
mutant was not able to induce RFP expression in rKSHV.219-Vero cells, excluding the 
possibility of possible kinase scaffolding side-effect.
Tumor cells in KS lesions express endothelial cell markers and are considered to be of 
endothelial cell origin. Indeed primary endothelial cells are susceptible for infection by 
KSHV in vitro. To further validate Pim-1 kinase in a biologically relevant cell model 
for KSHV infection, we repeated the KSHV reactivation assay in a human hybrid 
endothelial cell line, eA.hy926 cells, which were latently infected with rKSHV.219. The 
data revealed that Pim-1 also induced RFP expression in rKSHV.219-eA.hy926 cells, 
although the reactivation level by Pim-1 was stronger in Vero than in eA.hy926 cells, 
which	is	in	accordance	with	the	ability	to	obtain	higher	maximal	reactivation	efficiency	
in these cells by BacK50 infection and naB induction (Fig. 3 in I and Fig. 1A in II).
2. pim kinases are required for the viral reactivation (i, ii)
2.1. Ectopic expression of pim-2 and pim-3 induces KSHV reactivation
In the above gain-of-function screen utilizing a novel expression library for human 
protein kinase cdnAs, 480 individual, ectopically expressed human kinases were used 
to	examine	their	abilities	to	induce	KSHV	reactivation.	Pim-1	was	identified	through	the	
primary screen and secondary rescreen as a novel kinase involved in KSHV reactivation. 
As the Pim oncogenic serine/threonine kinase family includes three members, Pim-1, 
Pim-2	 and	 Pim-3,	 sharing	 significant	 sequence	 similarities	 and	 largely	 overlapping	
functions (Bachmann and Moroy, 2005; Bullock et al., 2005), we decided to examine 
the roles of all three Pim kinase family members in viral reactivation.
To this end, V5-tagged Pim-1, -2 or -3 cdnAs and an empty vector control were transiently 
transfected into latently infected rKSHV.219-Vero or rKSHV.219- eA.hy926 endothelial 
cells, which represent a biologically relevant KSHV infection model. After 48 h, basal 
reactivation was induced by BacK50 infection and RFP expression was monitored 30 h 
later. The analysis revealed that all three Pim kinases induced RFP expression to more 
than 3-fold compared to basal reactivation level (vector control, 2.5% RFP expression 
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in rKSHV.219-Vero, and 1.9% in rKSHV.219- eA.hy926), with Pim-1 as the strongest 
inducer (4- to 7-fold) in both cell lines (Fig. 1A and 1d in II). 
To	 study	where	 these	 three	 Pim	kinases	were	 sufficient	 to	 trigger	 the	 complete	 lytic	
replication cascade, expression of a late lytic protein K8.1 was analyzed in rKSHV.219-
Vero and -eA.hy926 cell lines transfected with the Pim kinases. In addition, the 
production of progeny virions in the supernatant of the transfected rKSHV.219-Vero or 
-eA.hy926 cells was measured by monitoring GFP expression in U2oS cells infected 
with the medium as described in Materials and Methods. All three wild type (wt) Pim 
kinases induced upregulation of K8.1 expression in rKSHV.219-Vero and -eA.hy926 
cell	lines,	as	well	as	GFP	expression	in	U2OS	target	cells	(Fig.	1B-F	in	II),	confirming	
the activation of the full lytic program.
To further assess whether kinase activity is required for the induction of viral reactivation, 
we performed the above described reactivation assays using mutant cdnAs of the Pim 
kinases, the ATP binding site of which was disrupted by a single point mutation (K67M 
in Pim-1, K61M in Pim-2, and K69M in Pim-3), rendering the kinases inactive (Fig. 
1E	in	I).	The	individual	Pim	kinase-deficient	(KD)	mutants	failed	to	induce	either	RFP	
or K8.1 expression in both rKSHV.219-Vero and -eA.hy926 cells (Fig. 1A, 1c, 1d 
and 1F in II). Accordingly, expression of the Pim-1Kd, -2Kd and –3Kd in both cell 
lines led to a clear reduction (maximally 10-fold) in GFP expression in target U2oS 
cells treated with rKSHV.219-Vero or -eA.hy926 cell supernantants (Fig. 1B and 1e 
in II), suggesting that the viral lytic reactivation as well as production of infectious 
virions were dependent on the Pim kinase activity. Furthermore, ectopic expression of 
the	irrelevant	kinases	CDK7	or	LKB1	did	not	induce	any	significant	reactivation	or	GFP	
expression in the U2oS target cells over the negative control (Fig. S1A and S1B in II), 
excluding a possible kinase scaffolding side-effect.
2.2. pim-1 and -3 are required in viral reactivation of KSHV-infected 
endothelial and b cells
To rule out the possibility that viral reactivation by Pim kinases was only observed as a 
result of over-expression, the selective and robust effect of RnAi on gene expression can 
be exploited as a research tool to evaluate the effect of knocking down the expression of 
these genes on viral reactivation. To this end, we silenced expression of Pim-1, -2 and 
-3	 individually	or	 simultaneously	by	 transfecting	siRNA	oligonucleotides	specific	 for	
Pim-1, -2 or -3, or with a nontargeting control siRnA into rKSHV.219-eA.hy926 cells. 
The	silencing	efficiency	was	evaluated	4	days	after	siRNA	transfection	and	the	efficient	
depletion	of	Pim-1	(85%),	Pim-2	(90%)	and	Pim-3	(80%)	expression	was	confirmed	by	
immunoblotting (Fig. 2A in II). 48 h after siRnA transfection, the cells were subjected 
to maximal reactivation by BacK50 infection and naB stimulation (RTA+naB) and 
the silencing effect on viral reactivation was examined by immunoblotting with K8.1 
antibody as well as by measuring the induction of RFP, and expression of GFP in target 
U2oS cells infected with the supernatant from reactivated/silenced rKSHV.219-eA.
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hy926 cells. Interestingly, depletion of Pim-1 and -3 expressions almost completely 
inhibited induction of RFP and K8.1 in rKSHV.219-eA.hy926 cells or GFP expression 
in U2oS cells, while simultaneous knockdown of Pim-1 and Pim-3 had a synergistic 
effect on inhibition of viral reactivation as observed by a greater reduction in RFP, GFP 
and K8.1 expression (Fig. 2 in II). However, Pim-2 silencing had very little effect on 
KSHV reactivation (Fig. 2 in II), suggesting that expression of Pim-1 and -3, but not 
Pim-2, is necessary for KSHV lytic reactivation under the reactivation conditions used 
here.
next we assessed the expression levels of endogenous Pim-1, -2 and -3 upon chemical 
reactivation of naturally KSHV-infected B cells to gain more insight into the biological 
relevance of Pim kinase-mediated KSHV reactivation. To this end, two PeL cell lines, 
BC-3	and	BCBL-1	cells	were	first	synchronized	 to	S	phase	by	serum	starvation	for	
24 h, and then cultured in the presence of serum for 16 h to increase the reactivation 
efficiency.	The	synchronized	cells	were	then	treated	with	20ng/ml	TPA	for	48	h	and	
the	late	lytic	marker	K8.1	level	was	analyzed	by	immunoblotting	to	confirm	efficient	
reactivation. Intriguingly, expression of Pim-1 and -3 was clearly up-regulated in 
reactivated PeL cells, whereas the expression of Pim-2 remained unchanged (Fig. 3 and 
S3 in II). It has been reported that Pim kinases are constitutively active whenever they 
are expressed, due to an unusual structure and conformation of the hinge region near 
the ATP-binding pocket (Bullock et al., 2005).  Therefore the increase in expression 
levels of Pim-1 and Pim-3 upon KSHV reactivation in PeL cells would correlate with 
their activity.
Similar to rKSHV.219-eA.hy926 cells, Pim-1 and -3 were also required for the PeL 
cells reactivation indicated by K8.1 level after transient silencing of Pim-1 or -3 by using 
siRNAs	(Fig.	3B	in	II).	In	accordance	with	the	findings	above,	depletion	of	Pim-2	had	
no effect on induction of K8.1 (Fig. 3B in II). Interestingly, although depletion of Pim-2 
expression had no effect on viral reactivation in PeL cells, it seemed to induce a post-
translational	modification	on	the	Pim-1	protein,	indicated	by	the	mobility	change	of	the	
Pim-1 band in the Western blot.
A previous study has suggested that Pim-2 is upregulated upon another herpesvisus, 
eBV infection and it enhances the activity of eBV viral nuclear antigen eBnA2 (Rainio 
et al., 2005). Another report indicates the upregulation of Pim-2 expression in KSHV 
infected cd34+ bone marrow cells (Mikovits et al., 2001). Therefore it is surprising 
that Pim-1 and Pim-3 seemed to co-operate in viral reactivation, whereas Pim-2 was 
not essential for KSHV reactivation either in de novo infected ecs or in the naturally 
infected PeL cells. It is possible that KSHV-infected cells require a threshold level of 
active Pim kinases to reactivate, which is beyond the endogenous Pim-2 level, and thus 
its depletion does not affect reactivation. However, the total Pim kinase activity may fall 
below	the	required	threshold	after	efficient	Pim-1	or	-3	silencing,	leading	to	inhibition	of	
viral reactivation upon depletion of either of them.
62 Results and Discussion 
2.3. pim-1 and -3 counteract laNa-mediated suppression of lytic 
replication
2.3.1. pim-1 and -3 interact with and phosphorylate laNa
LAnA can act as a transcriptional activator or repressor to modulate viral gene expression 
and LAnA-mediated transcriptional control helps to keep the virus in its latency cycle 
(Lan et al., 2005b; Verma et al., 2004). Pim-1 was shown to bind and phosphorylate KSHV 
LAnA protein upon co-expression of Pim-1 and LAnA in vitro (Bajaj et al., 2006). These 
data led us to investigate the interaction of Pim-1/-3 with LAnA and Pim-1/-3 mediated 
LAnA phosphorylation in KSHV infected cells. To address this question, whole cell 
extracts of untreated and TPA-treated PeL cells were immunoprecipitated with with anti-
Pim-1, -Pim-3, or control IgG antibodies and subjected to an in vitro kinase assay on co-
precipitated proteins. LAnA was shown to be co-precipitated with both Pim-1 and Pim-3 
only in the reactivated cells, but not in latent cells (Fig. 3B in I; Fig. 3c in II). There was 
no association of LAnA in the Pim-1 immunoprecipitates from the more concentrated, 
untreated	 latent	 BC-3	 extracts,	 confirming	 that	 the	 interaction	 requires	 induction	 of	
reactivation, and is not solely a result of increase in the Pim protein levels (Fig. S3 in II).
Moreover, we found that upon TPA or naB stimulation, the LAnA bands co-
immunoprecipitated with Pim-1 or -3 were phosphorylated in the autoradiograph from the 
IP-kinase assay, suggesting that LAnA was a substrate for Pim-1 and -3 in the reactivated 
cells (Fig. 3B in I; Fig. 3c in II). In accordance with the Pim silencing result, we did 
not observe interaction or phosphorylation of LAnA in the Pim-2 immunoprecipitates 
either in latent or reactivated PeL cells. collectively, these data suggest that LAnA was 
phosphorylated by Pim-1 and -3, but not Pim-2 kinase in the reactivated PeL cells.
2.3.2. pim-1 and pim-3 phosphorylate laNa at the N-terminus on serines 205 
and 206
Both n- and c-terminal LAnA domains tether episomes to the host chromosomes 
during mitosis and interphase through interaction with core histones H2A and H2B. In 
addition, LAnA also actively cooperates with a panel of chromosome-binding and origin 
recognition complex (oRcs) proteins to facilitate viral episomal replication (Stedman 
et al., 2004; Stedman et al., 2008; Verma et al., 2006). of note, the c-terminus of LAnA 
binds	specifically	 to	 sequences	within	 the	 terminal	 repeat	 (TR)	 regions	of	 the	KSHV	
episomal genome (Schwam et al., 2000; Verma et al., 2006; Viejo-Borbolla et al., 2005). 
To determine whether the n-terminus or c-terminus of LAnA is phosphorylated by Pim-
1 and -3, 293 cells were transfected with expression vectors for V5-tagged wt or mutant 
Pim-1 and -3, and phosphorylation of LAnA was analyzed by immunoprecipitation with 
anti-V5 antibody followed by an in vitro kinase assay, using recombinant n-terminal 
(GST-n-LAnA) and c-terminal (GST-c-LAnA) LAnA as substrates. Both Pim-
1 and -3 phosphorylated GST-n-LAnA while no phosphorylation was observed on 
GST-C-LANA	or	with	Pim-1KD	or	Pim-3KD	(Fig.	4A	 in	 II),	confirming	 that	LANA	
phosphorylation by Pim-1 and -3 in vitro occur on its n-terminus. 
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In addition, we were able to compete the phosphorylation signal on the 200 kda 
LAnA protein by adding GST-n-LAnA (which contains the Pim phosphosites) into 
the cell extracts used for the IP-kinase assay, whereas addition of GST-c-LAnA (with 
no Pim target sites) or GST only had no effect on the phosphorylation of the 200kda 
band	(Fig.	4D	in	II).	This	confirmed	that	the	200	kDa	phosphoprotein	is	indeed	LANA,	
and not another protein, such as a cellular transcription factor recruited by LAnA and 
phosphorylated by Pim. 
To further map the site of Pim-1 and -3 phosphorylation on the LAnA n-terminus, 
truncated versions of the GST-n-LAnA were used as substrates in the in vitro kinase 
assay as described above. A LAnA fragment between amino acids 200 and 340 was 
demonstrated to carry the critical residues for phosphorylation by Pim-1 and -3, and 
the	further	analysis	of	site-specific	LANA	phosphomutants	via	kinase	assay	and	mass	
spectrometry	revealed	that	serines	205	and	206	on	the	LANA	N-terminus	are	the	specific	
residues phosphorylated by Pim-1 and Pim-3 (Fig. 4 in II and data not shown). When 
these two critical serines were mutated into arginines (SS205/206RR), the LAnA mutant 
failed to be phosphorylated by either Pim-1 or -3, consistent with a previous report 
(Bajaj et al., 2006).
To further rule out the possibility that LAnA is phosphorylated by a protein that 
associates	with	Pim	kinase	 rather	 than	with	 the	Pim	kinase	 itself,	we	mixed	purified	
recombinant	Pim-1	kinase	 (wt	 and	kinase-deficient)	with	 recombinant,	 purified	GST-
LANA,	and	were	able	to	show	specific,	direct	phosphorylation	of	the	N-terminal	LANA	
by Pim-1 (Fig. 4e in II), demonstrating Pim-1 as a bona fide kinase responsible for the 
phosphorylation of LAnA.
2.3.3. phosphorylation of laNa counteracts its ability to inhibit transcription 
from the terminal repeat region
next we wanted to address the role of LAnA phosphorylation by Pim kinases in the 
viral	reactivation.	LANA	can	specifically	bind	to	the	LANA	binding	sites	1	and	2	(LBS1	
and LBS2) within the TR region of the KSHV genome, and binding of LAnA to the 
TR region confers transcriptional silencing of a subset of lytic genes in the vicinity of 
the TR (Garber et al., 2002; Verma et al., 2006). This prompted us to examine whether 
phosphorylation of LAnA by Pim-1 and Pim-3 would affect KSHV TR transcription. 
By using a luciferase reporter system consisting of multimerized TR repeats (pGL3-
7xTR), we detected a 10-fold transcriptional repression of the TR-containing reporters 
in the presence of LAnA in 293 cells. ectopic expression of Pim-1 or -3 counteracted 
the LAnA-mediated transcriptional repression of the TR-containing reporters in a dose-
dependent manner. However, in the absence of LAnA, expression of Pim-1 or -3 did 
not	 influence	 transcription	of	 the	 reporters,	 suggesting	 that	Pim-1	or	 -3	enhanced	 the	
transcription from reporters in an indirect manner (Fig. 5A in II).
To obtain direct evidence that phosphorylation of LAnA plays a key role in the de-
repression of TR transcription, a phosphosite mutant of LAnA (SS205/206RR) with 
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Pim-1 or Pim-3 and the pGL3-7xTR luciferase reporter construct were co-transfected, 
and the samples were subjected to luciferase reporter assays 48 h after transfection. 
The LAnA phosphosite mutant induced similar repression of luciferase activity as the 
wt	LANA,	which	was	not	 relieved	by	 the	co-expression	of	Pim-1	and	-3,	confirming	
that phosphorylation of these serine residues is required to relieve the LAnA-mediated 
inhibition of lytic gene transcription from the TR region (Fig. 5c in II). Interestingly, 
LANA	showed	affinity	for	two	other	regions	of	the	KSHV	genome,	albeit	to	a	lesser	degree	
than the TR repeats (cotter and Robertson, 1999), suggesting that alternate elements of 
the KSHV genome are possibly targeted by LAnA to maintain viral episomes in latency.
other studies support the role of phosphorylations of LAnA on LAnA-dependent 
transcription or dnA replication. The interaction between a nuclear protein RInG3 and 
LAnA results in phosphorylation of Ser/Thr residues within the c terminus of LAnA 
in in vitro	assays	(Platt	et	al.,	1999).	It	is	possible	that	RING3	itself	or	an	unidentified	
serine/threonine protein kinase recruited into the LAnA/ RInG3 complex is responsible 
for this phosphorylation, contributing to interaction of LAnA with local heterochromatin 
and its functional activities (Viejo-Borbolla et al., 2005). The eBV latent viral protein 
eBnA-1 clearly plays a role in the persistence and segregation of the latent viral episome 
that is formally analogous to that of KSHV LAnA. Interestingly, eBnA1 amino acids 
387 to 641 are phosphorylated in vitro by cdK1-, -2-, -5-, and -7/cyclin complexes 
and S393A mutation of eBnA-1 abrogates phosphorylation. This phosphorylation may 
have	a	specific	effect	on	EBNA1-dependent	transcription	or	EBV	episome	replication	
(Kang et al., 2011). Further investigation of the responsible kinase(s) for multiple 
phosphorylations of KSHV LAnA or its homologues may be necessary to understand 
the process more fully in the years to come.
2.3.4. pim phosphorylation on laNa counteracts its ability to repress RTa 
autoactivation
Besides inhibiting the TR-dependent viral gene transcription, LAnA can down-modulate 
the auto-activatation of RTA on its own viral promoter (deng et al., 2000; Lan et al., 
2004). We observed that the RTA responsive lytic gene K8.1 was induced by Pim-1 and 
-3 in KSHV-infected cells (Fig. 1c and 1F in II). However, RTA promoter is not located 
in the proximity of the TR region in the KSHV genome. To provide further support for 
the potential effect of Pim phosphorylation on LAnA’s ability to repress RTA responsive 
genes, luciferase assay using a RTA-Luc reporter (pGL2-oRF50p) was performed to 
measure the RTA autoactivation level. expression of LAnA led to a partial repression 
of the RTA-Luc reporter activity, which correlated with previous reports (deng et al., 
2000; Lan et al., 2004). Upon coexpression of wt Pim-1 or -3 together with RTA, Pim-1 
and -3 were both able to de-repress the RTA-Luc activity, suggesting that that expression 
of Pim-1 and -3 kinases can antagonize the ability of LAnA to inhibit autoactivation of 
the RTA promoter. Interestingly, in the absence of the Pim kinases, LAnA phosphosite 
mutant was able to repress the RTA-luciferase activity but to a lesser extent than the 
wt LAnA, and co-expression of Pim-1 and -3 could not reverse this repression (Fig. 
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5d in II). While the LAnA-induced inhibition of transcription from the TR region 
depends on direct binding of LAnA to dnA at LBS1 and LBS2, the suppression of RTA 
autoactivation occurs through direct binding of LAnA to RTA. Therefore the different 
mechanisms behind the repression of the TR region and the RTA promoter region by 
LAnA might explain this variation of LAnA-mediated inhibition of transcription of 
TR-Luc and RTA-Luc reporters.
other known gammaherpesviruses including rhesus rhadinovirus (RRV), herpesvirus 
saimiri (HVS), and murine herpesvirus 68 (MHV-68) also encode LAnA and RTA 
homologues. RRV LAnA, like KSHV LAnA, represses the transactivation ability of 
RRV RTA, and this repression is reversed by treatment with the histone deacetylase 
inhibitor TSA (deWire and damania, 2005). Similarly, the LAnA homologue in HVS 
can	repress	the	expression	of	the	HVS	RTA	(Schafer	et	al.,	2003).	These	findings	support	
our results and suggest that the counterbalance of the latent transactivator LAnA and 
the lytic transactivator RTA may be a common and evolutionarily conserved mechanism 
among	the	gammaherpesviruses.	This	eventually	defines	a	critical	control	point	between	
viral persistence latently and lytic replication and in turn results in a profound difference 
in overall viral load and pathogenesis within the infected host.
2.3.5. pim kinases have a moderate effect on laNa-dependent latent replication
In addition to its viral episome tethering function, LAnA is also necessary for latent 
replication of the genome (Grundhoff and Ganem, 2003). By using a mini-replicon 
system containing the minimal requirements for KSHV latent replication (Grundhoff 
and Ganem, 2003; Hu et al., 2002; Viejo-Borbolla et al., 2005) we tested the effect of 
Pim kinases on LAnA-dependent episome replication. our results indicate that all Pim 
kinases had a moderate inhibitory effect on minireplicon replication (Figure 6). 
Figure	6.	Ectopic	expression	of	Pim	proteins	moderately	reduces	the	efficiency	of	episome	
replication. (A) V5-tagged Pim1/2/3 expressing cdnAs were transfected together with 
pGTR4:73 plasmid (-), the pGTR4 vector alone (negative control), or (+) the pGTR4:73 vector 
also encoding for LAnA (positive control). The top panel shows episomal dnA linearized by the 
MfeI enzyme and resistant to the dpnI digestion. dpnI cuts only dnA with bacterial methylation 
pattern and therefore allows differentiation between transfected dnA of bacterial origin and the 
newly synthesized (replicated) dnA in the 293 cells. The bottom panel shows total episomal dnA 
(input) linearized with the MfeI enzyme. The peGFP plasmid does not replicate and therefore 
can be used as an input control. (B) Western blot showing expression of LAnA and Pim proteins.
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Interestingly, this effect did not require the kinase activity of Pim-1/-3 as replication 
was	reduced	also	upon	co-expression	of	the	kinase	deficient	forms.	Non-specific,	over-
expression related effects were ruled out by transfecting an expression vector coding 
for an irrelevant protein, which did not affect latent replication (data not shown). This 
suggests that inhibition of LAnA-dependent latent replication is due to binding of 
Pim kinases to LAnA rather than targeting LAnA by phosphorylation and is most 
likely based on a mechanism distinct from the one involved in Pim-mediated lytic 
reactivation.
2.4. pim kinases as potential novel targets for treatment of KSHV-
associated malignancies
In the previous experiments, chemicals (TPA and naB) were used to induce KSHV 
lytic	 reactivation.	However,	a	number	of	 immune	and	 inflammatory	 factors	 such	as	
IL-6	(Chang	et	al.,	2000;	Chatterjee	et	al.,	2002),	IFN-γ,	and	oncostatin	M	in	KS	and	
PeL tumor microenvironment have been shown to induce KSHV reactivation (ensoli 
and Sirianni, 1998; ensoli et al., 2001). Very interestingly, expression of Pim-1 is 
induced	by	a	number	of	cytokines,	such	as	IFN-α,	IFN-γ,	IL-3,	and	IL-6	(Bachmann	
and Moroy, 2005), which are associated with KSHV associated malignancies and 
suggested to modulate KSHV reactivation. It is therefore plausible that the presence 
of a variety of cytokines in the microenvironment of KSHV-associated tumors can 
lead to induction of Pim kinases, and therefore lead to viral reactivation in the affected 
tissues.
To address if physiological inducers of Pim kinases would induce KSHV reactivation, 
the expression levels of endogenous Pim-1 in PeL cells upon cytokine stimulation were 
analyzed.	3	h	after	IFN-γ	stimulation	in	BC-3	cells,	expression	of	Pim-1	was	already	
found	to	be	moderately	up-regulated	and	was	maintained	at	a	high	level	at	16	h	of	IFN-γ	
treatment, which correlated with the elevated expression of two lytic transcripts oRF50/
RTA (immediate-early transcript) and oRF57 (delayed-early transcript) in a quantitative 
real-time	PCR	analysis	6	hours	post	IFN-γ	treatment		(Fig.	6A	and	6D	in	II),	implying	that	
cytokine treatment lead to expression of viral lytic genes. Silencing of Pim-1 expression 
by	siRNA	led	to	a	significant	decrease	of	both	of	the	lytic	transcripts	(Fig.	6C	and	6D	in	
II), demonstrating the involvement of Pim-1 in activation of oRF50 and oRF57 lytic 
gene	transcription	in	IFN-γ	treated	PEL	cells.
To	further	address	if	Pim-1	phosphorylated	LANA	in	IFN-γ	stimulated	PEL	cells,	we	
performed Pim-1 IP-kinase assay to compare LAnA phosphorylation in untreated, 
IFN-γ-	 or	 TPA-treated	 BC-3	 cells.	 In	 accordance	 with	 the	 induction	 of	 lytic	 gene	
expression, LAnA was co-precipitated with Pim-1 and phosphorylated by Pim-1 upon 
IFN-γ	treatment	of	BC-3	cells	(Fig.	6B	in	II),	further	supporting	the	physiological	role	
for Pim-1 in KSHV reactivation. The role of Pim-1 and Pim-3 in the regulation of KSHV 
reactivation is summarized in Figure 7.
 Results and Discussion 67

    


	

   




 	

Figure 7. pim-1 and pim-3 as novel regulators of the KSHV lytic reactivation. This schematic 
model depicts the role of Pim-1 and Pim-3 in the regulation of KSHV reactivation. In latency, 
binding of LAnA to the LAnA binding sites 1 and 2 (LBS 1 and LBS2) at the terminal repeat (TR) 
region represses transcription from the TR region. In addition, LAnA can also repress transcription 
from the RTA promoter and inhibit RTA to autoactivate its own promoter, which is is essential 
to maintain the transcriptional repression of viral lytic genes. Upon stimulation by cytokines, 
TPA or naB, Pim-1 and -3 are up-regulated,and they interact with and phosphorylate LAnA. 
The phosphorylation by LAnA counteracts the LAnA–mediated inhibition of transcription from 
the TR region and drives its dissociation from the RTA-promoter (oRF50p), leading to viral 
reactivation.
As majority of latent infected cells are insensitive to anti-herpes drugs, in spite of major 
improvements in the treatment of KSHV-associated malignancies, overall survival of 
patients remains poor. The switch from latency to lytic replication is a critical decision 
in the KSHV viral life cycle and a sustained low level of reactivation contributes to 
tumor progression by producing new virions as well as providing favoring tumor 
microenvironment	rich	in	inflammatory	and	angiogenic	cytokines	(Grundhoff	and	Ganem,	
2004; Song et al., 2004). Therefore cellular factors and signaling pathways involved 
in lytic reactivation would represent promising targets in sensitizing tumor cells to the 
anti-viral therapy (Brown et al., 2005; curreli et al., 2005; Klass and offermann, 2005). 
our data established Pim-1 and -3 as key factors in KSHV reactivation and inhibition 
of	 either	Pim-1	or	 -3	 results	 in	 a	 significant	decrease	 in	 lytic	 replication.	As	animals	
lacking all three Pim genes are viable with a mild phenotype (Mikkers et al., 2004), 
small-molecule	inhibitors	targeting	Pim-1	and	-3	might	be	tolerated	without	significant	
side	effects.	The	unpublished	results	confirmed	the	efficacy	of	a	specific	Pim	inhibitor	to	
suppress viral lytic replication indicated by the expression of two lytic markers K8.1 and 
oRF59 (Figure 8). Therefore, targeting Pim kinases could be a promising approach for 
therapeutic intervention of KSHV associated tumors.
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Figure	8.	KSHV	lytic	replication	is	suppressed	by	a	specific	Pim	inhibitor.	Bc-3 cells were 
pre-treated of with different concentrations of the Pim inhibitor for six hours followed by co-
treatment with TPA (20ng/ml) or vehicle (dMSo) alone for an additional 24 hours. (A) The 
expression of lytic gene K8.1 was detected by qRT-PcR and (B) the expression of late lytic 
protein	ORF	59	was	detected	by	immunofluorescence.
3. KSHV reprograms lEC cells into a mesenchymal cell type 
through endothelial-to-mesenchymal transition (iii)
KS is an angiogenic tumor, which consists of proliferating cells with spindle-like 
morphology that form irregular microvascular channels (Boshoff et al., 1995). The origin 
of the spindle cells in KS lesions is still debated as they are composed of quite heterogenic 
populations of cells expressing markers of endothelial cells (dupin et al., 1999; Kaaya 
et	al.,	1995),	smooth	muscle	cells	and	fibroblasts	(Kaaya	et	al.,	1995;	Sturzl	et	al.,	1995;	
Weich et al., 1991; Werner et al., 1990). The prevailing view is that KS is derived from 
endothelial cells (ec) (Ganem, 2010) and thus various types of ecs infected with KSHV 
represent a relevant model system to study pathways involved in KSHV tumorigenesis 
as well as the role of viral genes in virus-induced cell transformation. (McAllister and 
Moses, 2007).
Mouse bone marrow endothelial-lineage cells transfected with KSHV Bacterial 
Artificial	Chromosome	(mECK36)	are	able	to	form	KS-like	tumors	in	nude	mice.	This	
KSHV malignancy is reversible (Mutlu et al., 2007). When these mecK36 cells lost the 
KSHV episome, they lost the tumorigenic potential in vivo. Intriguingly, mecK36 did 
not form colonies in soft agar assay in vitro, suggesting that the tumorigenic potential 
of KSHV on the endothelial precursors is dependent on the tissue microenvironment 
(Mutlu et al., 2007). In cell culture system, primary ecs are susceptible for infection 
by KSHV. However, primary ecs infected with wild-type KSHV do not readily acquire 
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properties of transformed cells, and tend to lose the viral episomal genomes upon 
culturing (Lagunoff et al., 2002). Moreover, KSHV evokes anti-proliferative, rather than 
proliferative responses in cultured ecs (Koopal et al., 2007), making aspects of KS 
tumorigenesis	difficult	to	study	in	a	2D	system.
3.1. KSHV induces extensive sprouting of lECs in 3d
To mimic the physiological microenvironment for the KSHV-infected ecs, we sought 
to identify here novel cellular pathways and virus-host interactions involved in KSHV 
pathogenesis by developing a cross-linked 3-dimensional (3d) organotypic system 
(Korff and Augustin, 1998) (Rowe and Weiss, 2008). Since spindle cells in KS tumors 
are positive for both Bec and Lec markers, and global gene expression analyses have 
demonstrated that the KS gene expression signature resembles more that of the infected 
Lecs than Becs (carroll et al., 2004; Hong et al., 2004; Wang et al., 2004a), we chose 
primary Lecs as the cell model to study.
Upon infection with KSHV, primary Lecs in culture adopted a spindle-cell like 
morphology. Based on the propensity of ecs to form spheroids under non-adherent 
conditions (Korff and Augustin, 1998), we prepared spheroids from KSHV-infected 
Lecs (K-Lecs) and uninfected control Lecs seven to ten days after infection to provide 
a more physiological environment for the cells. KSHV induced a dramatic outgrowth 
of	fibroblast-like	cells	in	the	LEC	spheroids	while	minimal	sprouting	was	observed	in	
uninfected control Lecs (Fig. 2A in III). These sprouts were progressing with time, and 
their	morphology	was	 sharp	 fibroblast-like,	 different	 from	 capillary	BEC	 sprouts.	 In	
addition, the KSHV major latent antigen LAnA was expressed in most of the sprouting 
cells (Fig. 3d in III).
To test if viruses are required for extensive sprouting of Lecs, KSHV was inactivated 
by	UV	light	and	the	loss	of	infectivity	was	confirmed	by	measuring	the	virus	titer.	As	
expected, minimal sprouting was observed in the UV-K-Lec spheroids, demonstrating 
that the K-Lec sprouting required infectious virus (Fig. 3A in III). Furthermore, 
to examine the correlation of the extent of sprouting with the virus infection, GFP 
expression was monitored in spheroids prepared from a 1:3 mixture of Lecs infected 
with the GFP-expressing recombinant rKSHV.219 (Vieira and o’Hearn, 2004) and 
control Lecs. confocal analysis revealed that the majority of sprouting cells are KSHV 
virus infected by counting the numbers of green sprouts, suggesting that infected cells 
are predominantly contributing to the sprouting (Fig. 3c in III).
3.2. KSHV induces endothelial-to-mesenchymal transition in lEC spheroids
Because	 of	 the	 fibroblast-like	 morphology	 of	 KLEC	 sprouts,	 we	 were	 interested	 in	
defining	the	differentiation	status	of	infected	cells	in	sprout	formation.	To	this	end,	the	
immunofluoresence	 staining	 of	 a	 series	 of	 antibodies	 against	 lymphatic	 endothelial	
and mesenchymal markers was applied in the 3d system. expression of endothelial 
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markers PecAM-1, Ve-cadherin as well as lymphatic markers VeGFR3, podoplanin 
and LYVe-1 was remarkably downregulated both in K-Lec spheroids as well as in 2d 
K-Lec cultures, which is in accordance with previous reports showing KSHV-induced 
downregulation of ec markers (Mansouri et al., 2006; Mansouri et al., 2008; Qian et al., 
2008; Wang et al., 2004a). Unexpectedly, expression of several mesenchymal proteins 
(aSMA,	transgelin,	N-cadherin,	fibronectin,	and	fibrous	vimentin)	was	strongly	induced	
in	the	sprouts	of	the	K-LEC	spheroids	(Fig.	2B	in	III),	which	was	further	confirmed	by	
qRT-PcR with a panel of additional mesenchymal markers (TAGLN, VIM, CDH2,CNN1, 
PDGFRB, COL1A1, and S100A4) induced in the K-Lec spheroids, but not in parental 
2d K-Lec cultures (Figure 2c in III), suggesting that the 3d environment triggered 
K-Lec to differentiate into a new, mesenchymal cell type via endMT (Potenta et 
al., 2008). during endMT process, cytoskeleton rearrangement is a prerequisite for 
polarized ecs transforming into non-polarized and motile mesenchymal cells. Indeed 
we found that nocodazole, which disrupts microtubules organization, was able to block 
the mesenchymal reprogramming, suggesting that a functional cytoskeletal network is 
necessary for the K-Lec mesenchymal reprogramming in 3d (Fig. S4B in III).
3.3. The Notch pathway regulates the KSHV-induced reprogramming of 
lECs
3.3.1.	Notch,	but	not	TGF-β,	initiates	the	KSHV-induced	EndMT
TGF-b and notch pathways have been demonstrated to activate endMT (Arciniegas et 
al., 2007; Medici et al., 2010; noseda et al., 2004; Potenta et al., 2008; Timmerman et al., 
2004).	Interestingly,	KSHV	infection	alone	did	not	significantly	induce	any	of	the	TGF- b 
targets in primary Lecs (Fig. S3B in III). To further elucidate if the KSHV-induced endMT 
is induced in response to TGF-b  activation, the K-Lec and control Lec spheroids were 
treated with the inhibitor of TGF-b downstream kinases ALK4, -5, -7 (SB431542) or a 
TGF-b blocking antibody (anti-TGF-b). Surprisingly, inhibition of TGF-b signaling by 
SB431542 or anti-TGF-b antibody had no effect on sprouting of the K-Lec spheroids or 
induction of mesenchymal transcripts (Fig. S3A, S3c in III and data not shown), indicating 
that TGF-b signaling is not the endMT inducer in KLec spheroids.
In comparison, inhibition of the notch pathway by gamma-secretase inhibitor (dAPT) 
or a soluble inhibitor of dll4/notch signaling (dll4-Fc) dramatically reduced the number 
of sprouts in the K-Lec spheroids compared to control Lec spheroids. Transcripts for 
mesenchymal markers were decreased in the notch inhibition, accordingly (Fig. 3, S3 
in III and data not shown). As notch has been shown to regulate viral lytic infection 
via functional interaction with RBPJ (chang et al., 2005a; Liang et al., 2002; Liang 
and Ganem, 2003; Liang and Ganem, 2004), we also addressed if notch inhibition 
influences	 the	 viral	 gene	 expression	 in	 3D	K-LECs.	 qRT-PCR	 results	 suggested	 that	
dAPT treatment led to a decrease in a panel of early and late lytic genes (oRF50, vIRF-
2,	ORF25,	and	K8.1)	without	significant	effect	on	latent	LANA	transcripts	(Fig.	S7D	in	
III),	confirming	the	role	of	Notch	in	viral	lytic	replication.
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3.3.2. vgpCR and vFlip are engaged in the reprogramming of lECs
Besides that notch is involved in KSHV lytic replication, recent reports demonstrated 
engagement of notch signaling in Lecs by two KSHV gene products vFLIP and vGPcR 
(emuss et al., 2009; Liu et al., 2009). This prompted us to investigate if these viral 
genes are involved in the KSHV-induced endMT. Lentivirus-mediated gain-of-function 
assay demonstrated that these two viral genes induced notch downstream targets and 
mesenchymal markers in 3d, which was inhibited by dAPT treatment (Fig. 4A-d in III). 
Silencing of vFLIP and vGPcR expression individually or simultaneously in K-Lecs 
by siRnAs reduced sprouting of the K-Lec spheroids for 30-50%, together with the 
reduction of aSMA	 and	 fibronectin	 positive	 sprouts	 in	 the	 corresponding	 K-LEC	
spheroids	(Fig.	4F-G	in	III),	confirming	that	vFLIP	and	vGPCR	coregulate	EndMT	in	
the context of the whole virus infection.
Notch 1-4 are reported to be expressed in KS tumors (curry et al., 2005; Liu et al., 2010) and 
consistent	with	previous	reports	(Emuss	et	al.,	2009),	we	confirmed	that	a	KSHV	latency	
protein (vFLIP) and a lytic protein (vGPcR) activate notch signaling pathway already 
in 2d. However, our results suggested that the transition into mesenchymal phenotype 
requires	both	a	microenvironment	provided	by	the	cross-linked	3D	fibrin	matrix,	and	intact	
microtubule dynamics to support the ingression into the 3d matrix. The data is distinct 
with the recent report that mural cell markers were induced in 2d cultured HPV-16 e6/e7-
immortalized Lecs stably infected by rKSHV.219 (Liu et al., 2010). This could be due to 
the sensitizing effect of ectopic e6 and e7, as overexpression of these genes is implicated 
in eMT induction (chamulitrat et al., 2009; Hellner et al., 2009).
3.3.3. KSHV induced EndMT and VEgF-stimulated (lymph)angiogenesis 
represent distinct biological processes 
The	 3D	 fibrin	 system	 has	 been	 broadly	 used	 in	 angiogenesis	 research	 to	 study	 EC	
sprouting. It has been reported that in 3d notch inhibition synergizes with VeGF 
to promote angiogenic sprouting of HUVecs (Becs) (Ridgway et al., 2006) and 
lymphangiogenesis of Lecs (Zheng et al., 2011). To clarify the notch involvement 
and consequences of VeGF stimulations in our K-Lec 3d system, 50ng/ml VeGF-A 
or VeGF-c were added to treat K-Lec spheroids. compared to unstimulated parental 
spheroids, VeGF-A or -c stimulated spheroids did not induce outgrowth of the 
mesenchymal-like sprouts rather than showing extensive capillary-like sprouts. These 
capillary sprouting cells maintained the expression of strong ec marker (PecAM) and 
did not express mesenchymal markers (aSMA,	fibronectin)	(Fig.	3G	in	III),	indicating	
that the KSHV-induced mesenchymal reprogramming of Lecs in 3d is a unique 
process induced and regulated by different biological stimuli than VeGF-A/c. As Notch 
signaling has been implicated in the regulation of cell fate decisions in different tissues 
and organs, our results suggest that notch may be a critical player determinant for the 
(lymph)angiogenic vs. mesenchymal fate of Lecs.
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3.4.	 Notch	activation	cooperates	with	MT1-MMP	and	PDGFR-β	in	the	
KSHV-EndMT
3.4.1. KSHV-induced EndMT endows primary lECs with invasive properties
To obtain a more comprehensive picture of the properties of 3d reprogrammed K-Lecs 
we	compared	 the	gene	expression	microarray	 (GEM)	profiles	of	K-LEC	spheroids	 to	
control	LEC	spheroids	three	days	after	embedding	to	fibrin.	3D	K-LEC	transcriptome	
analysis	revealed	significant	up-regulation	of	invasion	related	genes	(Fig.	5A-B	in	III),	
many of which were found to be also upregulated in KS biopsies (Fig. S5A-B in III) 
(Wang et al., 2004a). These results are correlated to the known role of endMT in cancer 
cell migration and invasion. In addition, certain invasive markers such as n-cadherin 
and	fibronection	were	deregulated	in	3D	K-LECs	(Fig.	2B	in	III),	and	the	tight-junction	
protein Zo-1 was also found to relocalize from the cell-cell contacts to more dispersed, 
cytoplasmic localization in the sprouts of K-Lec spheroids (Fig. 2d in III), further 
suggesting that the K-Lecs may acquire invasive potential upon reprogramming. 
3.4.2. MT1-MMp represents the major MMp involved in mesenchymal 
reprogramming of lECs
next we assessed the role of MMPs, the key enzymes in cancer cell invasion, in the 
K-Lec spheroid sprouting. To examine whether soluble or membrane-associated MMPs 
are required for sprouting, we used a broad-spectrum MMP inhibitor GM6001 and two 
tissue inhibitors of metalloproteinases TIMP1 and TIMP2. TIMP1 targets the secreted, 
soluble MMPs, including MMP1, -2 and -9, whereas TIMP2 targets both soluble and 
membrane bound MMPs (MT-MMPs) (Baker et al., 2002). While the treatment with 
TIMP1 had no effect on the K-Lec spheroids, GM6001 and TIMP2 dramatically inhibited 
sprouting, suggesting the involvement of MT-MMPs in the sprouting. Accordingly, a 
strong up-regulation of MMP14 (gene for MT1-MMP) was observed in 3d K-Lecs 
as well as in 2d cultures. The invasive properties of K-Lec cells were validated in an 
MT1-MMP-dependent functional invasion assay through a cross-linked collagen matrix 
(Rowe and Weiss, 2008; Sabeh et al., 2004) (Fig. 5d in III), further supporting that 
KSHV-induced endMT leads to MT1-MMP-dependent invasiveness. 
ectopic expression of MT1-MMP on the Lec revealed an induction of extensive 
outgrowth of sprouts with aSMA expression in Lec spheroids together with a panel 
of mesenchymal genes (Fig. 6c in III), whereas depletion of MT1-MMP led to a clear 
reduction of the sprouting of the K-Lec spheroids (Fig. 5F in III), further indicating that 
MT1-MMP	is	required	for	efficient	sprouting	of	the	K-LEC	spheroids	in	3D	fibrin,	and	
may represent the major MMP involved. Although primary Lecs normally express very 
low levels of membrane bound MMPs (Petrova et al., 2002), our results demonstrated that 
KSHV induces a substantial up-regulation of MT1-MMP in the infected Lecs, resulting 
in	 activities	 allowing	 the	 cells	 to	 invade	 3D	 fibrin	 and	 collagen.	This	 is	 remarkably	
distinct from the reported MT1-MMP expression pattern during angiogenesis where it is 
confined	largely	to	the	tip	endothelial	cell	of	the	sprouting	neovessels	(Yana	et	al.,	2007).
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3.4.3. a novel Notch-MT1-MMp is an important mediator of the KSHV-induced 
reprogramming of lECs
To	define	the	interplay	of	Notch	and	MT1-MMP	in	the	KSHV-induced	reprogramming	
and invasion, we examined the endMT markers in the K-Lec spheroids after MT1-
MMP silencing or notch inhibition. depletion of MT1-MMP had only a minor effect on 
expression of notch target genes HES1 and HEY1, while the treatment of K-Lecs with 
dAPT or dll4-Fc abolished the induction of MT1-MMP both in 2d (data not shown) and 
3d (Fig. 6A-B in III), indicating notch pathway as a previously unrecognized upstream 
regulator of MT1-MMP that was necessary to trigger the endMT in 3d. The data 
further	demonstrates	that	MT1-MMP	is	sufficient	to	provide	LECs	with	a	mechanism	to	
undergo endMT in 3d. Analogous to our MT1-MMP overexpressing Lecs, MT1-MMP 
has	 been	 shown	 to	 be	 sufficient	 to	 induce	 an	 invasive	EMT	program	 in	MCF7	 cells	
in 3d environment, although the cells retain their epithelial morphology in 2d culture 
(ota et al., 2009). While the mechanisms by which MT1-MMP can exert such global 
effects on Lec remain to be established, it is known that the cell invasion and growth 
promoting effects of MT1-MMP are associated to its ability to degrade downstream 
substrates	including	collagens,	fibrin,	laminin,	fibronectin	and	other	basement	membrane	
and interstitial matrix components or to hydrolyze growth factors or other growth and 
invasion modifying substrates in the pericellular spaces. It is also possible that genes 
involved in local ecM rigidity, cell shape and tension could be altered by MT1-MMP in 
a direct or indirect manner (Rowe and Weiss, 2008). 
An	interesting	finding	during	MT1-MMP	depletion	 in	KLEC	is	 that	PDGFRB  gene, 
a	known	effector/regulator	of	EMT	(Jechlinger	et	al.,	2006)	and	cell	invasion	in	fibrin	
(Lehti et al., 2005), was also downregulated in K-Lec spheroids. This concured with an 
earlier report linking notch 4-mediated up-regulation of PdGFR to endMT (noseda et 
al., 2004). Moreover, MT1-MMP has been found to interact with membrane receptors 
including integrins, VeGFRs, FGFRs, and PdGFRs, thus altering post-transcriptionally 
the receptor functions and cell phenotype (eisenach et al., 2010; Lehti et al., 2005; 
Sugiyama et al., 2010). Therefore, as a potent regulator of mesenchymal cell invasion, 
proliferation, and differentiation, PdGFR-b could act as a logical partner with MT1-
MMP in mediating endMT. To examine the involvement of PdGFR-b in endMT program 
induced by notch/MT1-MMP axis, we silenced PdGFR-b by using siRnA oligos in 
K-LECs	and	 analyzed	 the	 silencing	 efficiency,	 spheroid	 sprouting,	 and	 expression	of	
mesenchymal markers by qRT-PcR. Unexpectedly, silencing of PdGFR-b expression 
led to only a moderate reduction in spheroid sprouting and the induction of some of 
the assayed mesenchymal markers (Figure 6d-e). This suggests that in collaborating 
with notch/MT1-MMP signaling pathway, PdGFR-b plays a mild role to activate the 
transcriptional endMT program in 3d environment.
Taken together, the evidence indicates that in the context of K-Lecs, KSHV (mainly 
mediated by vFLIP and vGPcR) induces notch activation up-regulates MT1-MMP 
expression already in 2d KLecs. consistently, exogenous vGPcR expression has 
previously been linked to MT1-MMP upregulation in pulmonary arterial endothelial cells 
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(Shan et al., 2007). The	activated	Notch	and	MT1-MMP	are	not	sufficient	for	the	virus-
induced	EndMT	in	2D,	which	requires	the	cross-linked	3D	fibrin	matrix	and	a	functional	
microtubule network. The cross-talk between the PdGFR-b and notch pathways and a 
positive feedback mechanism through PdGFR and MT1-MMP signaling upon K-Lec 
sprouting further promote endMT in 3d culture (Fig. 6F in III).
3.5. Mesenchymal cells in KS lesions are infected with KSHV
The above results reveal a novel form of cell plasticity through the virus-induced notch-
MT1-MMP axis activation, providing a possible explanation for the origin of the KS 
tumor cells expressing heterogenic mesenchymal markers (Kaaya et al., 1995; Sturzl et 
al.,	1995;	Weich	et	al.,	1991;	Werner	et	al.,	1990).	Importantly,	by	double-label	fluorescent	
immunohistochemistry, we found cells co-expressing LAnA and the mesenchymal markers 
(aSMA and PdGFR-a) in the majority of the primary KS tumors. Although vimentin 
signal was observed also in uninfected cells, a quantitative image analysis revealed that 
the	LANA-positive	cells	 in	 the	 tumor	display	a	 stronger,	fibrous	vimentin	 signal	when	
compared to the LAnA-negative, non-infected cells (Fig. 1 in III). These results have 
profound implications for our understanding of KS-lesion histogenesis.
3.6.	 The	3D	KSHV-specific	transcriptome	has	implications	for	KS	
invasiveness
To further assess the biological relevance of our 3d system to KS, we compared the 
K-LEC	3D	transcriptome	to	previously	identified	gene	expression	profiles	of	KS	biopsies	
and 2d K-Lecs (Wang et al., 2004a). This analysis reveals a substantial number of 
genes co-regulated in all three-sample groups. Intriguingly, there are a number of genes 
with similar co-regulation between 3d and KS biopsies, including genes involved both 
in eMT/endMT and invasive processes (Fig. S5A and S5B in III). In addition, KSHV-
infected mesenchymal cells expressing MT1-MMP were found both at the invasive edge 
of KS tumors and within the nontumorigenic surrounding stromal tissue (Fig. 5e and S5e 
in III). Therefore, it is possible that the notch-MT1-MMP axis and downstream effectors 
are important mediators of KS cell invasion and dissemination from the primary site. In 
light	of	these	findings,	we	propose	that	the	KSHV-induced	invasive	mesenchymal	cell	
phenotype may contribute to the development of KS, and help to explain the progression 
of the disease through spread of the tumor foci into surrounding connective tissue.
3.7. The 3d system offers a permissive microenvironment for virus 
replication
To investigate whether the microenvironment milieu of the 3d culture and/or KSHV-
induced endMT would result in changes in the viral gene expression pattern, a 
timecourse mRnA analysis was performed for the expression of latent, early lytic and 
late lytic transcripts of the 3d and the parental 2d K-Lecs from the matching same-day 
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cultures. Interestingly, the microenvironment during spheroid formation (16-24 hours) 
in	the	non-adherent	conditions	before	embedding	into	fibrin	already	induced	substantial	
viral lytic gene expression (Fig. S7A in III). The subsequent time-course qRT-PcR 
analysis showed a time-dependent increase in the mRnA levels of the latent and lytic 
viral genes in the 3d cultured K-Lecs over 2d. This was supported by the concomitant 
immunofluorescence	analysis	that	revealed	enhanced	expression	of	LANA	and	ORF59	
in the K-Lec spheroids over 2d K-Lecs (Fig. 7A-c in III). The higher number of 
LANA	positive	cells	as	well	as	LANA	dots	per	cell	in	3D	was	further	confirmed	by	PCR	
for viral dnA that showed an increase of KSHV dnA in the 3d cells over 2d ones with 
time. This increase may result from elevated latent replication, re-infection of the cells 
by new progeny virions derived from an early activated lytic program upon the transfer 
from 2d to 3d, or improved maintenance of the viral episomes. 
To address whether the observed gene expression changes involve alterations in the 
epigenetic	 landscape	 of	 the	 viral	 genome,	we	 analyzed	 histone	modification	 patterns	
of viral episomes in cells grown under 2d or 3d conditions. However, an epigenetic 
landscape scanning of viral episomes in cells grown under 2d or 3d conditions showed 
that, at least on the side of viral chromatin, there is no fundamental differences between 
3D	or	2D	conditions	in	the	overall	distribution	profile	of	tri-methylated	histone	H3	at	
lysine	4	(H3K4-me3),	a	modification	that	is	commonly	associated	with	open	or	active	
chromatin	(Fig.	7D	in	III).	One	possible	reason	is	that	a	significantly	amount	of	naïve	
virion dnA in 3d is devoid of histones and thus refractory to immune precipitation, 
yet	will	register	in	the	input	channel	of	our	arrays,	resulting	in	artificially	lower	ChIP	
vs. input ratios. Another possible explanation for viral gene alteration in 3d would be 
the	loss	of	another	common	histone	modification,	H3K27-me3	that	has	previously	been	
found to be present on latent KSHV episomes and represses lytic gene expression via 
recruitment of polycomb repressor complexes (Gunther and Grundhoff, 2010; Toth et 
al.,	 2010).	A	more	detailed	 investigation	of	multiple	histone	modifications	 at	 various	
time points of 2d and/or 3d culturing would help to address this question.
The K-Lec spheroids showed a time-dependent increase in the expression of latent 
genes LAnA and vFLIP, as well as of a panel of lytic genes including vGPcR, over the 
parental 2d cultures, suggesting the importance of cell-cell interactions in 3d culture for 
virus replication and maintenance. our previous results suggest that notch signaling is 
activated in K-Lecs by the KSHV proteins vGPcR and vFLIP, which in turn leads to 
notch-dependent induction of MT1-MMP already in 2d KLecs. The notch/MT1-MMP 
axis is further enhanced in 3d microenvironment and activates the endMT program. Very 
interestingly, we found that culturing K-Lecs in 3d microenvironment led to changes in the 
viral gene expression involving increases in the vFLIP and vGPcR mRnA levels (Fig. 7A 
in III), indicating that an active virus replication and reactivation program in 3d condition 
could be the key mechanism to induce Lec cell reprogramming (Summarized in Figure 9).
In KS lesions, all the tumor cells are latently infected by KSHV and express latent 
genes such as vFLIP and LAnA. Several lines of evidence support the role of lytic viral 
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replication in KS tumorigenesis, and in addition to latent KSHV genes, genes expressed 
during the lytic replication cycle may contribute to pathogenesis either via paracrine 
effects	or	by	promoting	the	dissemination	of	the	virus.	Our	findings	suggest	that	the	3D	
model	may	also	provide	the	virus	a	permissive	cellular	microenvironment	for	efficient	
maintenance of infection, lytic replication and spread of the viral episomes. Hence, 
cellular and viral factors operative in the KSHV-induced endMT could offer attractive 
targets for intervention and treatment of KS.
 




			
     ­
	
	 
 




­
 


 
 

			




Figure 9. K-lECs cultures in 3d recapitulate pathogenetic aspects of KS. In 2d culture 
(top-left), KSHV infection of Primary Lecs has a tendency to establish latency and acquires 
partial KS-like phenotypic changes. However, cells tend to lose the viral episomal genomes 
upon culturing, suggesting that the tumorigenic potential of KSHV on the endothelium may 
be dependent on the microenvironment. 3d spheroids (bottom) provide the virus a permissive 
cellular microenvironment for active KSHV latent and lytic replication. Increased expression of 
lytic viral protein vGPcR and latent viral protein vFLIP activate notch-MT1-MMP-PdGFR-b 
signaling axis, giving rise to endMT, sprouting and invasiveness. endMT is characterized by 
downregulation of endothelial markers and the expression of mesenchymal markers, which were 
found co-distributed in the same cells with KSHV in primary KS tumor samples, suggesting that 
the 3d culture in this work may recapitulate the known heterogeneity of the cell types in KS 
tumors.
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CONCluSiONS aNd FuTuRE pROSpECTS
To date, accumulating evidence suggests that tumor viruses contribute to 15-20% 
of human cancers worldwide. KSHV is consistently associated with KS, the most 
widespread cancer in AIdS patients and a primary cause of cancer deaths in parts of 
Africa. In addition, KSHV causes devastating lymphoproliferative disorders such as 
PeL and Mcd, but the therapies against KSHV associated malignancies are limited.
A feature common to all oncogenic infectious agents is their long-term persistence 
in infected individuals, allowing time for the multi-step tumorigenesis. A sustained, 
although low level of reactivation can contribute to progression of KS by not only 
producing new virions but also by contributing to other aspects of KS pathogenesis, 
such	 as	 the	 production	 of	 inflammatory	 and	 angiogenic	 cytokines.	 This	 thesis	 work	
demonstrates that Pim-1 and -3 are critical regulators of the KSHV lytic replication, 
and that silencing of these kinases by RnAi leads to inhibition of the lytic replication 
cascade at an early stage. Thus, Pim kinases could represent potential novel cellular 
targets for therapeutic intervention. As animals lacking all three Pim genes are viable 
with a mild phenotype, one could anticipate that small-molecule inhibitors targeting 
Pim-1	and	-3	might	be	tolerated	without	significant	side	effects.	Moreover,	inhibition	of	
Pim kinases does not impose mutagenic pressure to viral genes, which will minimize the 
acquisition of drug resistance, and provide a long-lasting block to virus replication and 
the progression of the disease. 
A	specific	Pim	inhibitor	has	been	successfully	optimized	to	inhibit	reactivation	in	KSHV	
infected cell models (Sarek et al., manuscript in revision). The MdM2 antagonist, 
nutlin-3, is capable of effectively restoring p53 function and eradicating PeL tumor 
cells both in vitro and in vivo. However, an active viral reactivation program in some 
tumor cells, as a side-effect of nutlin-3 treatment, hampers the apoptotic response of p53 
restoration in vivo.	A	combination	treatment	of	Nutlin-3	and	the	specific	Pim	inhibitor	
restores the cell death of those nutlin-3 resistant PeL tumor cells. Thus, the future 
application of Pim inhibition as a treatment calls for further evaluation of its applicability 
as combinatorial therapies in relevant preclinical models for KSHV-malignancies in the 
future.
Another	important	finding	from	the	thesis	work	is	the	novel	Notch-MT1-MMP	signaling	
axis responsible for the functional properties of the emerging mesenchymal cells (motile, 
invasive), and its potential impact on KSHV pathogenesis. The notch pathway has been 
implicated in both KSHV latency (Lan et al., 2007), lytic replication (chang et al., 2005a; 
Lan et al., 2005a; Liang et al., 2002), in the survival of KSHV-infected lymphomas (Lan 
et	al.,	2009)	as	well	as	in	KS	tumors	(Curry	et	al.,	2005;	Liu	et	al.,	2009).	The	efficacy	of	
notch targeting can be evaluated as a pharmacological control and intervention in KS as 
well as similar pathological conditions in other cancers. In the future, the role of endMT 
in KS pathogenesis and progression would be a new research topic to study. Besides 
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the notch-MT1-MMP axis, the 3d in vitro viral oncogenesis system and appropriate 
preclinical	models	may	allow	the	identification	and	validation	of	a	plethora	of	potential	
new therapeutic targets or be used to test various types of drugs to alleviate this currently 
incurable cancer. 
KS spindle cells and their ontogeny are a matter of intense scrutiny in KS research. 
The effects of KSHV infection of endothelial cells in vitro (2d results in this thesis) 
poorly reproduce many markers found in KS spindle cells in vivo, and infected cells 
tend to lose viral episomes upon culturing. The 3d culture in the thesis work succeeds 
in inducing spindle cells that express mesenchymal markers characteristic of KS tumor 
cells. Therefore, testing the capability of transformed foci formation in the 3d culture 
system	 using	 cells	 from	 fresh	 KS	 tissue	 biopsies	 would	 strengthen	 the	 finding,	 and	
provide	relevance	beyond	artificial	manipulation in vitro. Moreover, the 3d culture is 
able to provide a permissive microenvironment for continuous viral replication and 
persistence. Since cultures from primary KS lesions lose KSHV after several passages 
in vitro, 3d methods can be used to test the possibility of generating actual KS cell lines 
retaining the viral genome, and retention of the expression of KSHV pathogenic genes.
oncogenic viruses have served as important experimental models to identify and 
investigate molecular events and regulatory networks that are critical for cancer 
development	and	progression.	The	finding	of	a	novel	mechanism	of	KSHV	pathogenesis	
in an in vitro 3d context shows that sophisticated tissue culture techniques such as 3d 
spheroid assays can be critical to gain insights into in vivo viral oncogenesis mechanisms. 
In this regard, the current research would motivate other investigations of in vivo-specific	
mechanisms of tumor virus pathogenesis that may be reproduced in vitro.
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